TKS-/published_papers/52853180 Ryohei Sumitani Hirokazu Miki Shingen Nakamura Masafumi Nakamura Taiki Hori Yusaku Maeda Masahiro Oura Kimiko Sogabe Hikaru Yagi Mamiko Takahashi Takeshi Harada Shiro Fujii Naoto Okada Susumu Nishio Tetsu Tomonari Masahiro Abe Ken-Ichi Matsuoka Novel noninvasive parameters for diagnosis of liver involvement in patients with systemic AL amyloidosis. Liver involvement in systemic immunoglobulin light-chain (AL) amyloidosis is diagnosed by an increase in liver size and/or elevated serum alkaline phosphatase (ALP) levels. However, novel diagnostic approaches that reflect the organ-specific characteristics of liver involvement are needed. Shear wave elastography (SWE) is a noninvasive and repeatable technique for measuring tissue stiffness. In this study, we evaluated the clinical significance of SWE and serum biochemistry tests in the diagnosis of AL amyloidosis with liver involvement. Twenty-five patients with systemic AL amyloidosis were examined. Eight patients were diagnosed with liver involvement according to the current consensus criteria. In patients with and without liver involvement, hepatic shear wave velocity (SWV) was 1.93 ± 0.39 versus 1.36 ± 0.11 m/sec (p = 0.00099), and the gamma-glutamyltranspeptidase (γ-GTP) level was 165 ± 131 versus 36 ± 28 U/L (p = 0.00222). Receiver-operating characteristic curve analysis showed that SWV and γ-GTP levels had favorable diagnostic accuracy for liver involvement. Of note, two patients with liver involvement who achieved organ response showed a decrease in both SWV and γ-GTP levels. These results suggest that SWV and γ-GTP are useful for establishing accurate organ-specific diagnosis and response criteria for liver involvement in AL amyloidosis. International journal of hematology 123 2 247 255 20260200 10.1007/s12185-025-04082-1 41143947 TKS-/published_papers/52724677 Mizuki Yoshimoto Shin-Ichiro Yanagiya Hiroki Takanari Takeshi Honda Yusaku Maeda Ryohei Sumitani Masahiro Oura Kimiko Sogabe Takeshi Harada Shiro Fujii Shingen Nakamura Yoshimi Bando Koichi Tsuneyama Itsuro Endo Masahiro Abe Ken-Ichi Matsuoka Hirokazu Miki Development of a rapid and novel diagnostic technique for cardiac amyloidosis using Raman spectroscopy. Although the prognosis of cardiac amyloidosis has improved with the development of therapies, the time required for disease typing remains a critical issue. We investigated the potential of Raman spectroscopy for the more rapid diagnosis and typing of cardiac amyloidosis. Heart biopsies were collected from patients with the AL (4) and ATTR (4) types of cardiac amyloidosis, and tissue sections were subjected to Raman microscopy. A principal component analysis (PCA) of spectral data was performed and receiver operating characteristic (ROC) curves were created to confirm the accuracy of discriminating between amyloid-deposition and non-deposition sites, and between AL and ATTR. The steep peak at 1680 cm-1, reflecting the β-sheet structure, was useful for detecting the amyloid-deposition region. By restricting the spectral analysis to amyloid-deposition sites, AL and ATTR were discriminated by principal components with a characteristic broad peak at 1520-1540 cm-1, which was also observed in the Raman spectrum of AL, but not ATTR. The area under ROC curve discriminating AL and ATTR was 0.78. PCA of the Raman spectra of cardiac biopsies has the potential not only to detect amyloid-deposition sites in tissue but also to rapidly discriminate between the AL and ATTR types of cardiac amyloidosis. Research square null null 20250625 10.21203/rs.3.rs-6795517/v1 40678255 TKS-/published_papers/48573524 Yusuke Inoue Hirofumi Tenshin Jumpei Teramachi Ryohei Sumitani Asuka Oda Yusaku Maeda Masahiro Oura Kimiko Sogabe Tomoko Maruhashi Mamiko Takahashi Shiro Fujii Shingen Nakamura Hirokazu Miki Tomoyo Hara Itsuro Endo Kumiko Kagawa Shuji Ozaki Masahiro Hiasa Takeshi Harada Masahiro Abe Elotuzumab-mediated ADCC with Th1-like Vγ9Vδ2 T cells to disrupt myeloma-osteoclast interaction. Multiple myeloma (MM) cells and osteoclasts (OCs) activate with each other to cause drug resistance. Human Th1-like Vγ9Vδ2 (γδ) T cells, important effectors against tumors, can be expanded and activated ex vivo by the aminobisphosphonate zoledronic acid in combination with IL-2. We previously reported that the expanded γδ T cells effectively targeted and killed OCs as well as MM cells. Because the expanded γδ T cells expressed CD16 on their surface, we investigated the utilization of the expanded γδ T cells for antibody-dependent cellular cytotoxicity (ADCC). Although the expanded γδ T cells alone induced cell death in MM cell lines, the addition of the anti-SLAMF7 monoclonal antibody elotuzumab (ELO) further enhanced their cytotoxic activity only against SLAMF7-expressing MM cell lines and primary MM cells. Intriguingly, ELO was also able to enhance γδ T cell-induced cell death against OCs cultured alone, and against both MM cells and OCs in their coculture settings. SLAMF7 was found to be highly expressed in OCs differentiated in vitro from monocytes by receptor activator of nuclear factor-κ B ligand and M-CSF, although monocytes only marginally expressed SLAMF7. These results demonstrate that SLAMF7 is highly expressed in both MM cells and OCs, and that the ex vivo-expanded γδ T cells can exert ELO-mediated ADCC against SLAMF7-expressing MM cells and OCs besides their direct cytotoxic activity. Further study is warranted for the innovative utilization of γδ T cells. Cancer science null null 20241118 10.1111/cas.16401 39557586 TKS-/published_papers/52711960 多発性骨髄腫における低線量全身CTの画質評価と多能性 (一社)日本血液学会 日本血液学会学術集会 86 O2 3 20241000 TKS-/published_papers/52398090 Yusaku Maeda Shoichiro Takao Shiori Morita Shin Kondo Michiko Yamashita Ryohei Sumitani Masahiro Oura Kimiko Sogabe Mamiko Takahashi Shiro Fujii Takeshi Harada Hirokazu Miki Masahiro Abe Shingen Nakamura Quality of skeletal muscles during allogeneic stem-cell transplantation: a pilot study. OBJECTIVES: This study investigated the muscle fat fraction (FF) and muscle-related parameters before and after allogeneic hematopoietic stem cell transplantation (HSCT). METHODS: Fat and water signals were derived from the in-phase and out-of-phase MR signal intensities of the pelvis and thigh using the two-point Dixon technique. They were analysed using Synapse Vincent, and muscle quality was evaluated using the FF. The muscle mass was assessed by measuring the thigh and gluteal muscle areas using a manual trace on the MR image. The association between the muscle FF and clinical data was retrospectively determined. RESULTS: This study included 11 patients (6 males). Their mean age was 42.7 years, and eight had leukaemia. Eight were assessed at a mean of 65.4 days post-HSCT. The hip and thigh skeletal muscle FFs were not significantly different during HSCT. The grip and lower limb muscle strengths decreased significantly after HSCT. Patients with low FFs before transplantation tended to lose muscle strength, and the increase in FF and decrease of muscle strength were correlated. CONCLUSIONS: Muscle strength and quantity decrease during the early phase after HSCT, especially in patients with low FF muscles. Therefore, interventions based on muscle quality and quantity are essential. BMJ supportive & palliative care null null 20241001 10.1136/spcare-2024-005070 39353719 TKS-/published_papers/49510051 ADAR1とZBP1を標的とする1q増幅多発性骨髄腫に対する新規治療法の開発 (一社)日本血液学会 日本血液学会学術集会 86 O1 4 20241000 TKS-/published_papers/52398092 Mamiko Takahashi Shin Kondo Kumiko Kagawa Masafumi Nakamura Yusaku Maeda Ryohei Sumitani Hikaru Yagi Masahiro Oura Kimiko Sogabe Takeshi Harada Shiro Fujii Hirokazu Miki Itsuro Endo Masahiro Abe Shingen Nakamura Skeletal muscle mass during chemotherapy for haematological malignancies: a retrospective study. OBJECTIVE: This study investigated whether baseline or alteration in muscle mass affects complications during chemotherapy or overall survival (OS) in haematological malignancies. METHODS: Skeletal Muscle Index (SMI) was evaluated by bioimpedance analysis before and after chemotherapy in patients with haematological malignancies, and the association between muscle mass and clinical data was retrospectively analysed. RESULTS: Exactly 104 patients were enrolled, with a mean age of 62.2 years. SMI was 7.85 and 6.08 in male and female patients under 65 years and 7.10 and 5.92 over 65 years, before chemotherapy, respectively. Lower baseline SMI was not correlated with worse OS in total patients (p=0.915). After a median measurement interval of 30 days after chemotherapy (n=67), body weight and SMI decreased by 2.73% and 2.87% (mean), respectively. The decrease in body weight correlated with the loss of trunk muscle mass (R2=0.2107) but was more strongly associated with the loss of lower limbs muscle mass (R2=0.3985). The muscle mass of lower limbs significantly decreased in lymphoma patients who experienced febrile neutropenia (-0.42% vs -6.04%, p=0.040). OS significantly decreased in lymphoma patients with loss of lower limbs muscle ≥2.8% (p=0.0327). CONCLUSIONS: Muscle loss occurred following anticancer treatments, significantly contributing to worse outcomes. Body composition assessment and relevant multimodal prevention of muscle loss may be vital for patients receiving chemotherapy for haematological malignancies. BMJ supportive & palliative care 14 2 195 199 20240517 10.1136/spcare-2024-004870 38569748 TKS-/published_papers/49540170 住谷 龍平 三木 浩和 岡村 和美 前田 悠作 大浦 雅博 曽我部 公子 八木 ひかる 高橋 真美子 丸橋 朋子 原田 武志 藤井 志朗 中村 信元 尾矢 剛志 安倍 正博 佐藤 亜紀 KRAS変異を認めた治療抵抗性Rosai-Dorfman病の1例 (一社)日本血液学会-東京事務局 臨床血液 1882-0824 65 5 473 473 20240500 TKS-/published_papers/46186462 Yusuke Inoue Asuka Oda Yusaku Maeda Ryohei Sumitani Masahiro Oura Kimiko Sogabe Tomoko Maruhashi Mamiko Takahashi Shiro Fujii Shingen Nakamura Hirokazu Miki Masahiro Hiasa Jumpei Teramachi Takeshi Harada Masahiro Abe Ex vivo expansion and activation of Vγ9Vδ2 T cells by CELMoDs in combination with zoledronic acid. As multiple myeloma (MM) progresses, immune effector cells decrease in number and function and become exhausted. This remains an insurmountable clinical issue that must be addressed by development of novel modalities to revitalize anti-MM immunity. Human Vγ9Vδ2 T (Vδ2+ γδ T) cells serve as the first line of defense against pathogens as well as tumors and can be expanded ex vivo from peripheral blood mononuclear cells (PBMCs) upon treatment with amino-bisphosphonates in combination with IL-2. Here, we demonstrated that next-generation immunomodulators called cereblon E3 ligase modulators (CELMoDs), as well as lenalidomide and pomalidomide, expanded Th1-like Vδ2+ γδ T cells from PBMCs in the presence of zoledronic acid (ZA). However, the expansion of Th1-like Vδ2+ γδ T cells by these immunomodulatory drugs was abolished under IL-2 blockade, although IL-2 production was induced in PBMCs. BTN3A1 triggers phosphoantigen presentation to γδ T-cell receptors and is required for γδ T-cell expansion and activation. ZA but not these immunomodulatory drugs upregulated BTN3A1 in monocytes. These results suggest that immunomodulatory drugs and ZA have cooperative roles in expansion of Th1-like Vδ2+ γδ T cells, and provide the important knowledge for clinical application of human Vδ2+ γδ T cells as effector cells. International journal of hematology null null 20240406 10.1007/s12185-024-03763-7 38581458 TKS-/published_papers/46186467 Kimiko Sogabe Shingen Nakamura Yoshiki Higa Hirokazu Miki Asuka Oda Tomoko Maruhashi Ryohei Sumitani Masahiro Oura Mamiko Takahashi Masafumi Nakamura Yusaku Maeda Tomoyo Hara Hiroki Yamagami Shiro Fujii Kumiko Kagawa Shuji Ozaki Kiyoe Kurahashi Itsuro Endo Ken-Ichi Aihara Emiko Nakaue Masahiro Hiasa Jumpei Teramachi Takeshi Harada Masahiro Abe Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors. Resistance to proteasome inhibitors (PIs) has emerged as an important clinical issue. We investigated the mechanisms underlying multiple myeloma (MM) cell resistance to PIs. To mimic their pharmacokinetic/pharmacodynamic (PK/PD) profiles, MM cells were treated with bortezomib and carfilzomib for 1 h at concentrations up to 400 and 1,000 nM, respectively. Susceptibility to these PIs markedly varied among MM cell lines. Pulsatile treatments with PIs suppressed translation, as demonstrated by incorporation of puromycin at 24 h in PI-susceptible MM.1S cells, but not PI-resistant KMS-11 cells. Inhibition of β5 subunit activity decreased at 24 h in KMS-11 cells, even with the irreversible PI carfilzomib, but not under suppression of protein synthesis with cycloheximide. Furthermore, the proteasome-degradable pro-survival factors PIM2 and NRF2 acutely accumulated in MM cells subjected to pulsatile PI treatments. Accumulated NRF2 was trans-localized into the nucleus to induce the expression of its target gene, HMOX1, in MM cells. PIM and Akt inhibition restored the anti-MM effects of PIs, even against PI-resistant KMS-11 cells. Collectively, these results suggest that increased synthesis of β5 proteasome subunit and acute accumulation of PIM2 and NRF2 reduce the anti-MM effects of PIs. International journal of hematology 119 3 303 315 20240300 10.1007/s12185-023-03705-9 38245883 TKS-/published_papers/46819477 Shin ichiro Yanagiya Takeshi Honda Hiroki Takanari Kimiko Sogabe Shingen Nakamura Yoshimi Bando Koichi Tsuneyama Masahiro Abe Hirokazu Miki Raman microspectroscopy for label-free diagnosis of amyloid light-chain amyloidosis in various organs Journal of Raman Spectroscopy 1097-4555 null null 20240000 10.1002/jrs.6665 2-s2.0-85188503323 TKS-/published_papers/52761795 ラマン分光法と主成分分析を用いた心アミロイドーシスに対する新規迅速診断法 (一社)日本血液学会 日本血液学会学術集会 85 533 533 20231000 TKS-/published_papers/46186491 1q増幅骨髄腫微小環境でのSLAMF7が介在する炎症ネットワーク (一社)日本血液学会 日本血液学会学術集会 85 41 41 20231000 TKS-/published_papers/42953168 Masahiro Oura Takeshi Harada Asuka Oda Jumpei Teramachi Atsushi Nakayama Ryohei Sumitani Yusuke Inoue Yusaku Maeda Kimiko Sogabe Tomoko Maruhashi Mamiko Takahashi Shiro Fujii Shingen Nakamura Hirokazu Miki Masafumi Nakamura Tomoyo Hara Hiroki Yamagami Kiyoe Kurahashi Itsuro Endo Hiroo Hasegawa Hiroshi Fujiwara Masahiro Abe Therapeutic efficacy of the resorcylic acid lactone LL‐Z1640‐2 for adult T‐cell leukaemia/lymphoma eJHaem null null 20230727 10.1002/jha2.758 TKS-/published_papers/52761799 ラマン分光法を用いたALアミロイドーシスの新規迅速診断法の開発(Development of a novel technique for rapid diagnosis of AL amyloidosis by Raman spectroscopy) (一社)日本骨髄腫学会 International Journal of Myeloma 2187-3143 13 3 120 120 20230500 TKS-/published_papers/47366943 骨髄腫細胞の内在的および外因子によるBCMA発現制御機構(Intrinsic and extrinsic regulation of BCMA expression in myeloma cells) (一社)日本骨髄腫学会 International Journal of Myeloma 2187-3143 13 3 90 90 20230500 TKS-/published_papers/44298946 骨髄腫の進展における可溶性SLAMF7による炎症惹起の役割(The role of soluble SLAMF7-mediated inflammation in myeloma progression) (一社)日本骨髄腫学会 International Journal of Myeloma 2187-3143 13 3 92 92 20230500 TKS-/published_papers/43126549 Jumpei Teramachi Hirokazu Miki Shingen Nakamura Masahiro Hiasa Takeshi Harada Masahiro Abe Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents. INTRODUCTION: Multiple myeloma (MM) is a malignancy of plasma cells with characteristic bone disease. Despite recent great strides achieved in MM treatment owing to the implementation of new anti-MM agents, MM is still incurable and bone destruction remains a serious unmet issue in patients with MM. APPROACH: In this review, we will summarize and discuss the mechanisms of the formation of bone disease in MM and the available preclinical and clinical evidence on the treatment for MM bone disease. CONCLUSIONS: MM cells produce a variety of cytokines to stimulate receptor activator of nuclear factor-κB ligand-mediated osteoclastogenesis and suppress osteoblastic differentiation from bone marrow stromal cells, leading to extensive bone destruction with rapid loss of bone. MM cells alter the microenvironment through bone destruction where they colonize, which in turn favors tumor growth and survival, thereby forming a vicious cycle between tumor progression and bone destruction. Denosumab or zoledronic acid is currently recommended to be administered at the start of treatment in newly diagnosed patients with MM with bone disease. Proteasome inhibitors and the anti-CD38 monoclonal antibody daratumumab have been demonstrated to exert bone-modifying activity in responders. Besides their anti-tumor activity, the effects of new anti-MM agents on bone metabolism should be more precisely analyzed in patients with MM. Because prognosis in patients with MM has been significantly improved owing to the implementation of new agents, the therapeutic impact of bone-modifying agents should be re-estimated in the era of these new agents. Journal of bone and mineral metabolism 41 3 388 403 20230500 10.1007/s00774-023-01403-4 36856824 TKS-/published_papers/40107346 Takeshi Harada Hiroto Ohguchi Asuka Oda Michiyasu Nakao Jumpei Teramachi Masahiro Hiasa Ryohei Sumitani Masahiro Oura Kimiko Sogabe Tomoko Maruhashi Mamiko Takahashi Shiro Fujii Shingen Nakamura Hirokazu Miki Kumiko Kagawa Shuji Ozaki Shigeki Sano Teru Hideshima Masahiro Abe Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase. Multiple myeloma (MM) preferentially expands and acquires drug resistance in bone marrow. We herein examined the role of histone deacetylase 1 (HDAC1) in the constitutive activation of the master transcription factor IRF4 and the pro-survival mediator PIM2 kinase in MM cells. The knockdown or inhibition of HDAC1 by the class I HDAC inhibitor MS-275 reduced the basal expression of IRF4 and PIM2 in MM cells. Mechanistically, the inhibition of HDAC1 decreased IRF4 transcription through histone hyperacetylation and inhibiting the recruitment of RNA polymerase II at the IRF4 locus, thereby reducing IRF4-targeting genes, including PIM2. In addition to the transcriptional regulation of PIM2 by the HDAC1-IRF4 axis, PIM2 was markedly up-regulated by external stimuli from bone marrow stromal cells and IL-6. Up-regulated PIM2 contributed to the attenuation of the cytotoxic effects of MS-275. Class I HDAC and PIM kinase inhibitors cooperatively suppressed MM cell growth in the presence of IL-6 and in vivo. Therefore, the present results demonstrate the potential of the simultaneous targeting of the intrinsic HDAC1-IRF4 axis plus externally activated PIM2 as an efficient therapeutic option for MM fostered in bone marrow. Blood advances null null 20220921 10.1182/bloodadvances.2022007155 36129197 TKS-/published_papers/39741890 Hiroki Yamada Rio Ohmori Naoto Okada Shingen Nakamura Kumiko Kagawa Shiro Fujii Hirokazu Miki Keisuke Ishizawa Masahiro Abe Youichi Sato A machine learning model using SNPs obtained from a genome-wide association study predicts the onset of vincristine-induced peripheral neuropathy. Vincristine treatment may cause peripheral neuropathy. In this study, we identified the genes associated with the development of peripheral neuropathy due to vincristine therapy using a genome-wide association study (GWAS) and constructed a predictive model for the development of peripheral neuropathy using genetic information-based machine learning. The study included 72 patients admitted to the Department of Hematology, Tokushima University Hospital, who received vincristine. Of these, 56 were genotyped using the Illumina Asian Screening Array-24 Kit, and a GWAS for the onset of peripheral neuropathy caused by vincristine was conducted. Using Sanger sequencing for 16 validation samples, the top three single nucleotide polymorphisms (SNPs) associated with the onset of peripheral neuropathy were determined. Machine learning was performed using the statistical software R package "caret". The 56 GWAS and 16 validation samples were used as the training and test sets, respectively. Predictive models were constructed using random forest, support vector machine, naive Bayes, and neural network algorithms. According to the GWAS, rs2110179, rs7126100, and rs2076549 were associated with the development of peripheral neuropathy on vincristine administration. Machine learning was performed using these three SNPs to construct a prediction model. A high accuracy of 93.8% was obtained with the support vector machine and neural network using rs2110179 and rs2076549. Thus, peripheral neuropathy development due to vincristine therapy can be effectively predicted by a machine learning prediction model using SNPs associated with it. The pharmacogenomics journal 22 4 241 246 20220700 10.1038/s41397-022-00282-8 35752658 TKS-/published_papers/37854952 Shin Kondo Tatsuro Inoue Takashi Saito Yuka Kawamura Ayane Katayama Masafumi Nakamura Ryohei Sumitani Mamiko Takahashi Masahiro Oura Kimiko Sogabe Takeshi Harada Shiro Fujii Shingen Nakamura Hirokazu Miki Kumiko Kagawa Nori Sato Rei Ono Masahiro Abe Shinsuke Katoh Allogeneic haematopoietic stem cell transplantation and patient falls: impact of lower extremity muscle strength. OBJECTIVES: Patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT) have a higher risk of falls than those receiving other therapies for haematological disorders. This study aimed to investigate the impact of pretransplant lower extremity muscle strength (LEMS) on post-transplant falls. METHODS: In this retrospective cohort study, patients aged ≥18 years who underwent allo-HSCT were included. All data were extracted from medical records. LEMS was defined as the knee extension force measured by a handheld dynamometer divided by the patient's weight. The receiver operating characteristic (ROC) curve was used to calculate the optimal LEMS cut-off value for prediction of falls. Patients were categorised into low and normal LEMS groups based on the cut-off value. The impact of pretransplant LEMS on post-transplant falls was analysed using a Cox proportional hazards model. RESULTS: In total, 101 patients were analysed. During the observation period, falls occurred in 32 patients (31.7%). The ROC curve analysis results showed that the optimal LEMS cut-off value for prediction of falls was 45.4% per body weight. In multivariate analysis, pretransplant low LEMS was a significant predictor of falls in model 1 with patient characteristics as a confounding factor and model 2 with medications-inducing falls as a confounding factor, respectively (model 1: HR 3.23, 95% CI 1.37 to 7.64; model 2: HR 2.82, 95% CI 1.20 to 6.59). CONCLUSIONS: Pretransplant LEMS was a significant predictor of post-transplant falls. The results of this study may help to prevent falls in patients undergoing allo-HSCT. BMJ supportive & palliative care null null 20220509 10.1136/bmjspcare-2022-003582 35534187 TKS-/published_papers/40807572 RNA編集酵素ADAR1を標的にする1q増幅骨髄腫細胞に対する治療法の開発(Therapeutic impact of targeting RNA editing enzyme ADAR1 on myeloma cells with 1q amplification) (一社)日本骨髄腫学会 International Journal of Myeloma 2187-3143 12 3 90 90 20220500 TKS-/published_papers/40807566 TAK1阻害は骨髄腫の細胞間相互作用による骨破壊と薬剤耐性を改善する(TAK1 inhibition ameliorates bone destruction and drug resistance by skewed intercellular communication in myeloma) (一社)日本骨髄腫学会 International Journal of Myeloma 2187-3143 12 3 132 132 20220500 TKS-/published_papers/40807561 骨髄腫に対する抗体免疫療法へのTh1様γδT細胞の応用(Leverage of Th1-like γδT cells into antibody-mediated immunotherapy against myeloma) (一社)日本骨髄腫学会 International Journal of Myeloma 2187-3143 12 3 144 144 20220500 TKS-/published_papers/40807552 破骨細胞はSLAMF7を強発現し可溶性SLAMF7を産生する(Osteoclasts robustly express SLAMF7 and secrete soluble SLAMF7) (一社)日本骨髄腫学会 International Journal of Myeloma 2187-3143 12 3 150 150 20220500 TKS-/published_papers/40807547 プロテアソーム阻害薬のパルス投与の骨代謝への影響(The impact of pulsatile proteasome inhibitor on bone metabolism) (一社)日本骨髄腫学会 International Journal of Myeloma 2187-3143 12 3 152 152 20220500 TKS-/published_papers/39100635 Hirokazu Miki Shingen Nakamura Masahiro Oura Masafumi Nakamura Ryohei Sumitani Kimiko Sogabe Mamiko Takahashi Tomoko Maruhashi Takeshi Harada Shiro Fujii Hirofumi Hamano Masateru Kondo Naoto Okada Itsuro Endo Masahiro Abe The importance of retaining physical functions to prevent skeletal-related events in multiple myeloma patients with bone disease. This study was undertaken to identify baseline conditions and triggering factors for skeletal-related events (SRE) in multiple myeloma (MM) patients treated with denosumab. During the median follow-up of 17 months, SRE occurred in 6 out of 52 newly diagnosed patients and in 5 out of 23 relapsed/refractory patients. Bone fractures occurred by falling down due to orthostatic hypotension and/or muscle weakness in three out of four cases with amyloid light-chain (AL) amyloidosis. A loss of balance and falling down appear to be triggering factors for SRE, especially in frail MM patients with AL amyloidosis, indicating the importance of retaining physical functions to prevent SRE. EJHaem 3 2 480 483 20220500 10.1002/jha2.402 35846024 TKS-/published_papers/41423430 高原 由実子 三木 浩和 中村 信元 中村 昌史 住谷 龍平 大浦 雅博 曽我部 公子 高橋 真美子 丸橋 朋子 原田 武志 藤井 志朗 安倍 正博 岡本 秀樹 岡田 直人 矢野 由美子 高橋 真理 青田 桂子 尾崎 修治 HIV感染症および後天性免疫不全症候群患者の臨床的特徴と今後の課題 徳島医学会 四国医学雑誌 0037-3699 78 1-2 89 89 20220400 TKS-/published_papers/37795069 Minori Takei Naoto Okada Shingen Nakamura Kumiko Kagawa Shiro Fujii Hirokazu Miki Keisuke Ishizawa Masahiro Abe Youichi Sato A Genome-Wide Association Study Predicts the Onset of Dysgeusia Due to Anti-cancer Drug Treatment. Dysgeusia is a major side effect of anti-cancer drug treatment. Since dysgeusia significantly lowers the patient's QOL, predicting and avoiding its onset in advance is desirable. Accordingly, aims of the present study were to use a genome-wide association study (GWAS) to identify genes associated with the development of dysgeusia in patients taking anti-cancer drugs and to predict the development of dysgeusia using associated single nucleotide polymorphisms (SNPs). GWAS was conducted on 76 patients admitted to the Department of Hematology, Tokushima University Hospital. Using Sanger sequencing for 23 separately collected validation samples, the top two SNPs associated with the development of dysgeusia were determined. GWAS identified rs73049478 and rs41396146 SNPs on the retinoic acid receptor beta (RARB) gene associated with dysgeusia development due to the administration of anti-cancer drugs. Evaluation of the two SNPs using 23 validation samples indicated that the accuracy rate of rs73049478 was relatively high (87.0%). Thus, the findings of the present study suggest that the rs73049478 SNP of RARB can be used to predict the onset of dysgeusia caused by the administration of anti-cancer drugs. Biological & pharmaceutical bulletin 45 1 114 117 20220101 10.1248/bpb.b21-00745 34657909 TKS-/published_papers/37663003 Shin Kondo Kumiko Kagawa Takashi Saito Masahiro Oura Kimiko Sogabe Takeshi Harada Shiro Fujii Shingen Nakamura Hirokazu Miki Nori Sato Rei Ono Masahiro Abe Shinsuke Katoh Allogeneic haematopoietic stem cell transplantation-clinical outcomes: impact of leg muscle strength. OBJECTIVES: Muscle strength decline is reported to predict mortality in many cancers. However, there is little knowledge of the relation between muscle strength decline and clinical outcomes of allogeneic haematopoietic stem cell transplantation (allo-HSCT). This study aimed to determine the impact of pre-transplant lower extremity muscle strength (LEMS) on post-transplant overall survival (OS) and non-relapse mortality (NRM). METHODS: In this retrospective cohort study, 97 adult patients underwent allo-HSCT during 2012-2020. LEMS was defined as knee extension force divided by patient's body weight. The patients were divided into low and high LEMS groups based on pre-transplant LEMS. OS was measured using the Kaplan-Meier method and the Cox proportional hazards model. The cumulative incidence of NRM was evaluated using the Fine and Gray method, with relapse considered as a competing risk event. RESULTS: Probability of OS was significantly lower in the low LEMS groups (HR 2.48, 95% CI 1.20 to 5.12, p=0.014) than in the high LEMS group on multivariate analysis. Five-year OS was 25.8% and 66.4% in the low and high LEMS groups, respectively. Risk of NRM was significantly higher in the low LEMS group (HR 4.49, 95% CI 1.28 to 15.68, p=0.019) than in the high LEMS group. The cumulative incidence of NRM was 41.4% and 11.1% in the low and high LEMS groups, respectively. CONCLUSIONS: Pre-transplant LEMS was a significant factor in predicting OS and NRM. BMJ supportive & palliative care null null 20211223 10.1136/bmjspcare-2021-003256 34949601 TKS-/published_papers/41423434 西條 早希 中村 信元 三木 浩和 谷口 早紀 岡本 秀樹 富永 誠記 岡田 直人 矢野 由美子 高橋 真理 青田 桂子 菅 俊行 渡邊 浩良 大坂 朱美 安倍 正博 徳島大学病院における先天性血友病患者(成人例)の実態調査 移行期医療の重要性 徳島医学会 四国医学雑誌 0037-3699 77 5-6 261 268 20211200 TKS-/published_papers/39869728 西條 早希 中村 信元 三木 浩和 谷口 早紀 岡本 秀樹 岡田 直人 矢野 由美子 高橋 真理 青田 桂子 菅 俊行 渡邊 浩良 大坂 朱美 安倍 正博 当院における先天性血友病患者(成人例)の実態調査 移行期医療の重要性 徳島医学会 四国医学雑誌 0037-3699 77 5-6 301 301 20211200 TKS-/published_papers/47366946 ATLの治療標的としてのPIMキナーゼの有用性(Efficacious therapeutic potential of targeting PIM kinases in ATL) (一社)日本血液学会 日本血液学会学術集会 83 PS 2 20210900 TKS-/published_papers/40807613 CELMoDsを用いたγδT細胞増幅法とエロツズマブによるγδT細胞の抗骨髄腫作用増強法の開発(Expansion of γδ T cells by CELMoDs and enhancement of their anti-myeloma effects by elotuzumab) (一社)日本血液学会 日本血液学会学術集会 83 OS2 5 20210900 TKS-/published_papers/40807600 PIMとAkt阻害による骨髄腫細胞のプロテアソーム阻害薬感受性の増強(Sensitization of myeloma cells to proteasome inhibitors by PIM and Akt inhibition) (一社)日本血液学会 日本血液学会学術集会 83 OS2 3 20210900 TKS-/published_papers/40807595 CELMoDsとHDAC阻害による骨髄腫細胞のIRF4-SLAMF7経路の抑制(Down-regulation of the IRF4-SLAMF7 axis in MM cells by CELMoDs and HDAC inhibition) (一社)日本血液学会 日本血液学会学術集会 83 OS2 4 20210900 TKS-/published_papers/40807589 TAK1阻害は骨髄腫増殖と骨破壊を惹起する細胞間コミュニケーションを改善する(TAK1 inhibition ameliorates skewed intercellular communication to elicit MM growth and bone loss) (一社)日本血液学会 日本血液学会学術集会 83 OS2 5 20210900 TKS-/published_papers/47124240 Ryohei Sumitani Taiki Hori Jumpei Murai Shiyori Kawata Masahiro Oura Kimiko Sogabe Mamiko Takahashi Takeshi Harada Shiro Fujii Hirokazu Miki Kumiko Kagawa Masahiro Abe Shingen Nakamura Acute myeloid leukemia developing with acute pancreatitis mimicking autoimmune pancreatitis Japanese Society of Internal Medicine Internal Medicine 1349-7235 60 11 1753 1757 20210601 10.2169/internalmedicine.4916-20 33456032 2-s2.0-85107419442 TKS-/published_papers/40807641 温故知新 骨髄腫細胞と破骨細胞を標的とするTh1様γδT細胞とエロツズマブの併用療法の開発(Development of combinatory treatment of Th1-like γδ T cells with elotuzumab against osteoclasts as well as myeloma cells) (一社)日本骨髄腫学会 International Journal of Myeloma 2187-3143 11 2 53 53 20210500 TKS-/published_papers/40807632 骨髄腫細胞のプロテアソーム阻害薬の耐性機序におけるPIM2とAkt活性およびNRF2蓄積の役割(Mechanisms for the resistance to proteasome inhibitors in myeloma cells: the role of PIM2 and Akt kinase activation and NRF2 accumulation) (一社)日本骨髄腫学会 International Journal of Myeloma 2187-3143 11 2 85 85 20210500 TKS-/published_papers/40807627 HDAC阻害薬とIMiDsの骨髄腫細胞のCD38とSLAMF7発現に及ぼす影響(Effects of HDAC inhibitors and IMiDs on CD38 and SLAMF7 expression in MM cells) (一社)日本骨髄腫学会 International Journal of Myeloma 2187-3143 11 2 86 86 20210500 TKS-/published_papers/39100654 温故知新 骨髄腫骨関連事象の発生予防における身体機能維持の重要性(The importance of retaining physical functions to prevent SRE in multiple myeloma) (一社)日本骨髄腫学会 International Journal of Myeloma 2187-3143 11 2 55 55 20210500 TKS-/published_papers/37935016 温故知新 骨髄腫骨関連事象の発生予防における身体機能維持の重要性(The importance of retaining physical functions to prevent SRE in multiple myeloma) (一社)日本骨髄腫学会 International Journal of Myeloma 2187-3143 11 2 55 55 20210500 TKS-/published_papers/39869732 石田 卓也 三木 浩和 高橋 真美子 中村 昌史 水口 槙子 住谷 龍平 大浦 雅博 曽我部 公子 丸橋 朋子 原田 武志 藤井 志朗 賀川 久美子 安倍 正博 岡本 秀樹 岡田 直人 矢野 由美子 高橋 真理 友成 哲 中村 信元 青田 桂子 渡邊 浩良 HIV感染血友病患者における臨床的特徴と今後の課題 徳島医学会 四国医学雑誌 0037-3699 77 1-2 118 118 20210400 TKS-/published_papers/34979524 石田 卓也 三木 浩和 高橋 真美子 中村 昌史 水口 槙子 住谷 龍平 大浦 雅博 曽我部 公子 丸橋 朋子 原田 武志 藤井 志朗 賀川 久美子 安倍 正博 岡本 秀樹 岡田 直人 矢野 由美子 高橋 真理 友成 哲 中村 信元 青田 桂子 渡邊 浩良 HIV感染血友病患者における臨床的特徴と今後の課題 徳島医学会 四国医学雑誌 0037-3699 77 1-2 118 118 20210400 TKS-/published_papers/47123364 Mamiko Takahashi Ryohei Sumitani Taiki Hori Jumpei Murai Shiyori Kawata Masahiro Oura Kimiko Sogabe Takeshi Harada Shiro Fujii Hirokazu Miki Kumiko Kagawa Masahiro Abe Shingen Nakamura Intravenous busulfan-based conditioning with autologous stem cell transplantation for refractory b-cell lymphoma with central nervous system involvement University of Tokushima Journal of Medical Investigation 1349-6867 68 1 196 201 20210000 10.2152/jmi.68.196 33994471 2-s2.0-85106640806 TKS-/published_papers/43245502 菅崎 幹樹 徳永 尚樹 池亀 彰茂 中尾 隆之 大浦 雅博 三木 浩和 長井 幸二郎 高山 哲治 A case of congenital prekallikrein deficiency discovered by preoperative screening 術前スクリーニングで偶然発見された先天性プレカリクレイン欠乏症の1症例 (一社)日本臨床衛生検査技師会 医学検査 2188-5346 70 1 132 137 20210100 TKS-/published_papers/35031615 大浦 雅博 中村 信元 堀 太貴 曽我部 公子 原田 武志 藤井 志朗 三木 浩和 賀川 久美子 小林 智子 尾矢 剛志 安倍 正博 結節性紅斑と悪性腫瘍関連血球貪食症候群を惹起した骨髄異形成症候群の1例 (一社)日本血液学会-東京事務局 臨床血液 1882-0824 61 10 1542 1542 20201000 TKS-/published_papers/35016858 天真 寛文 アシテル・モハナッド 寺町 順平 日浅 雅博 谷本 幸多朗 清水 宗 比嘉 佳基 原田 武志 大浦 雅博 曽我部 公子 中村 信元 三木 浩和 遠藤 逸朗 田中 栄二 松本 俊夫 安倍 正博 抗腫瘍薬が誘導するROSは破骨細胞分化を促進する Xanthine oxidase阻害剤febuxostatの治療効果 (一社)日本骨代謝学会 日本骨代謝学会学術集会プログラム抄録集 1349-0761 38 148 148 20201000 TKS-/published_papers/35016853 谷本 幸多朗 日浅 雅博 天真 寛文 清水 宗 Ashter Mohannad 比嘉 佳基 寺町 順平 原田 武志 中村 信元 三木 浩和 遠藤 逸朗 田中 栄二 松本 俊夫 安倍 正博 不動は骨吸収と骨髄腫進展を促進させる (一社)日本骨代謝学会 日本骨代謝学会学術集会プログラム抄録集 1349-0761 38 149 149 20201000 TKS-/published_papers/34822365 中村 昌史 三木 浩和 大浦 雅博 川田 知代 堀 太貴 村井 純平 住谷 龍平 曽我部 公子 高橋 真美子 原田 武志 藤井 志朗 中村 信元 賀川 久美子 菅崎 幹樹 徳永 尚樹 池亀 彰茂 森下 英理子 安倍 正博 クロスミキシングテストの特徴的な所見が診断の契機となったプレカリクレイン欠乏症の1例 (一社)日本血液学会-東京事務局 臨床血液 1882-0824 61 10 1537 1538 20201000 TKS-/published_papers/34658167 中村 昌史 三木 浩和 大浦 雅博 川田 知代 堀 太貴 村井 純平 住谷 龍平 曽我部 公子 高橋 真美子 原田 武志 藤井 志朗 中村 信元 賀川 久美子 菅崎 幹樹 徳永 尚樹 池亀 彰茂 森下 英理子 安倍 正博 クロスミキシングテストの特徴的な所見が診断の契機となったプレカリクレイン欠乏症の1例 (一社)日本血液学会-東京事務局 臨床血液 1882-0824 61 10 1537 1538 20201000 TKS-/published_papers/29749470 Michihiro Nakamura Koichiro Hayashi Junna Nakamura Chihiro Mochizuki Takuya Murakami Hirokazu Miki Shuji Ozaki Masahiro Abe Near-Infrared Fluorescent Thiol-Organosilica Nanoparticles That Are Functionalized with IR-820 and Their Applications for Long-Term Imaging of in Situ Labeled Cells and Depth-Dependent Tumor in Vivo Imaging American Chemical Society (ACS) Chemistry of Materials 1520-5002 null null 20200824 10.1021/acs.chemmater.0c01414 TKS-/published_papers/40798054 岡田 直人 神農 麻里奈 中村 信元 三木 浩和 渡辺 浩良 合田 光寛 中馬 真幸 武智 研志 座間味 義人 桐野 靖 中村 敏己 寺岡 和彦 安倍 正博 石澤 啓介 血液凝固因子製剤の在庫適正化に向けた取り組みによる薬剤廃棄額の削減効果 (一社)日本病院薬剤師会 日本病院薬剤師会雑誌 1341-8815 56 7 803 808 20200700 TKS-/published_papers/40798052 岡田 直人 神農 麻里奈 中村 信元 三木 浩和 渡辺 浩良 合田 光寛 中馬 真幸 武智 研志 座間味 義人 桐野 靖 中村 敏己 寺岡 和彦 安倍 正博 石澤 啓介 血液凝固因子製剤の在庫適正化に向けた取り組みによる薬剤廃棄額の削減効果 (一社)日本病院薬剤師会 日本病院薬剤師会雑誌 1341-8815 56 7 803 808 20200700 TKS-/published_papers/29515102 Keiichiro Watanabe Ariunzaya Bat-Erdene Hirofumi Tenshin Qu Cui Jumpei Teramachi Masahiro Hiasa Asuka Oda Takeshi Harada Hirokazu Miki Kimiko Sogabe Masahiro Oura Ryohei Sumitani Yukari Mitsui Itsuro Endo Eiji Tanaka Makoto Kawatani Hiroyuki Osada Toshio Matsumoto Masahiro Abe Reveromycin A, a novel acid-seeking agent, ameliorates bone destruction and tumor growth in multiple myeloma. Haematologica null null 20200625 10.3324/haematol.2019.244418 32586903 TKS-/published_papers/29515113 Jumpei Teramachi Hirofumi Tenshin Masahiro Hiasa Asuka Oda Ariunzaya Bat-Erdene Takeshi Harada Shingen Nakamura Mohannad Ashtar So Shimizu Masami Iwasa Kimiko Sogabe Masahiro Oura Shiro Fujii Kumiko Kagawa Hirokazu Miki Itsuro Endo Tatsuji Haneji Toshio Matsumoto Masahiro Abe TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma. Along with the tumor progression, the bone marrow microenvironment is skewed in multiple myeloma (MM), which underlies the unique pathophysiology of MM and confers aggressiveness and drug resistance in MM cells. TGF-β-activated kinase-1 (TAK1) mediates a wide range of intracellular signaling pathways. We demonstrate here that TAK1 is constitutively overexpressed and phosphorylated in MM cells, and that TAK1 inhibition suppresses the activation of NF-κB, p38MAPK, ERK and STAT3 to decrease the expression of critical mediators for MM growth and survival, including PIM2, MYC, Mcl-1, IRF4, and Sp1, along with a substantial reduction in the angiogenic factor VEGF in MM cells. Intriguingly, TAK1 phosphorylation was also induced along with upregulation of vascular cell adhesion molecule-1 (VCAM-1) in bone marrow stromal cells (BMSCs) in cocultures with MM cells, which facilitated MM cell-BMSC adhesion while inducing IL-6 production and receptor activator of nuclear factor κ-Β ligand (RANKL) expression by BMSCs. TAK1 inhibition effectively impaired MM cell adhesion to BMSCs to disrupt the support of MM cell growth and survival by BMSCs. Furthermore, TAK1 inhibition suppressed osteoclastogenesis enhanced by RANKL in cocultures of bone marrow cells with MM cells, and restored osteoblastic differentiation suppressed by MM cells or inhibitory factors for osteoblastogenesis overproduced in MM. Finally, treatment with the TAK1 inhibitor LLZ1640-2 markedly suppressed MM tumor growth and prevented bone destruction and loss in mouse MM models. Therefore, TAK1 inhibition may be a promising therapeutic option targeting not only MM cells but also the skewed bone marrow microenvironment in MM. Haematologica null null 20200409 10.3324/haematol.2019.234476 32273474 TKS-/published_papers/29515107 Mohannad Ashtar Hirofumi Tenshin Jumpei Teramachi Ariunzaya Bat-Erdene Masahiro Hiasa Asuka Oda Kotaro Tanimoto So Shimizu Yoshiki Higa Takeshi Harada Masahiro Oura Kimiko Sogabe Shingen Nakamura Shiro Fujii Ryohei Sumitani Hirokazu Miki Kengo Udaka Mamiko Takahashi Kumiko Kagawa Itsuro Endo Eiji Tanaka Toshio Matsumoto Masahiro Abe The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat. Receptor activator of NF-κB ligand (RANKL), a critical mediator of osteoclastogenesis, is upregulated in multiple myeloma (MM). The xanthine oxidase inhibitor febuxostat, clinically used for prevention of tumor lysis syndrome, has been demonstrated to effectively inhibit not only the generation of uric acid but also the formation of reactive oxygen species (ROS). ROS has been demonstrated to mediate RANKL-mediated osteoclastogenesis. In the present study, we therefore explored the role of cancer-treatment-induced ROS in RANKL-mediated osteoclastogenesis and the suppressive effects of febuxostat on ROS generation and osteoclastogenesis. RANKL dose-dependently induced ROS production in RAW264.7 preosteoclastic cells; however, febuxostat inhibited the RANKL-induced ROS production and osteoclast (OC) formation. Interestingly, doxorubicin (Dox) further enhanced RANKL-induced osteoclastogenesis through upregulation of ROS production, which was mostly abolished by addition of febuxostat. Febuxostat also inhibited osteoclastogenesis enhanced in cocultures of bone marrow cells with MM cells. Importantly, febuxostat rather suppressed MM cell viability and did not compromise Dox's anti-MM activity. In addition, febuxostat was able to alleviate pathological osteoclastic activity and bone loss in ovariectomized mice. Collectively, these results suggest that excessive ROS production by aberrant RANKL overexpression and/or anticancer treatment disadvantageously impacts bone, and that febuxostat can prevent the ROS-mediated osteoclastic bone damage. Cancers 12 4 null null 20200409 10.3390/cancers12040929 32283857 TKS-/published_papers/34979552 遠藤 優香 田島 穂澄 岡田 直人 中村 信元 賀川 久美子 藤井 志朗 三木 浩和 石澤 啓介 安倍 正博 佐藤 陽一 機械学習を用いたゲノム情報によるシタラビン投与の副作用発現予測モデルの構築 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 140 26M am07S 20200300 TKS-/published_papers/34979549 武井 みのり 岡田 直人 中村 信元 賀川 久美子 藤井 志朗 三木 浩和 石澤 啓介 安倍 正博 佐藤 陽一 遺伝情報を用いた機械学習による抗がん剤投与の味覚障害発現予測モデルの構築 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 140 26M am08S 20200300 TKS-/published_papers/41045652 藤井 志朗 大浦 雅博 曽我部 公子 高橋 真美子 原田 武志 中村 信元 賀川 久美子 安倍 正博 井上 雄介 池亀 彰茂 三木 浩和 臍帯血移植が奏効した治療抵抗性肝脾型T細胞リンパ腫の1例 徳島医学会 四国医学雑誌 0037-3699 75 5-6 221 226 20191200 TKS-/published_papers/24878641 Naoto Okada Masayuki Chuma Momoyo Azuma Shingen Nakamura Hirokazu Miki Hirofumi Hamano Mitsuhiro Goda Kenshi Takechi Yoshito Zamami Masahiro Abe Keisuke Ishizawa Effect of serum concentration and concomitant drugs on vancomycin-induced acute kidney injury in haematologic patients: a single-centre retrospective study. PURPOSE: Appropriate use of vancomycin (VCM) is important in preventing acute kidney injury (AKI). Because of the high frequency of VCM use for febrile neutropenia and concomitant use of other nephrotoxic drugs, haematologic patients have a different nephrotoxic background compared with patients with other diseases. Therefore, it is unclear whether the risk factors of VCM-induced AKI identified in other patient groups are also applicable to haematologic patients. Herein, we performed a single-centre retrospective analysis to identify the factors associated with VCM-induced AKI in haematologic patients. METHODS: We retrospectively analysed 150 haematologic patients to whom VCM was administered between April 2010 and March 2018 at Tokushima University Hospital. VCM-induced AKI was defined according to Kidney Disease Improving Global Outcomes (KDIGO) criteria. Multivariate logistic regression analyses were performed to identify risk factors for VCM-induced AKI. RESULTS: Seventeen patients had VCM-induced AKI. Multivariate analysis revealed that the risk factors of VCM-induced AKI were an initial VCM trough concentration of > 15 mg/L and concomitant use of tazobactam/piperacillin (TAZ/PIPC) and liposomal amphotericin B (L-AMB). Patients with an initial VCM trough concentration of < 10 mg/L showed significantly lower efficacy in febrile neutropenia. Interestingly, concomitant L-AMB use increased the incidence of VCM-induced AKI in a VCM concentration-dependent manner, whereas concomitant TAZ/PIPC increased the incidence in a VCM concentration-independent manner. CONCLUSIONS: The optimal initial VCM trough concentration was 10-15 mg/L in haematologic patients, considering safety and effectiveness. There were differences in the effect of VCM-induced AKI between nephrotoxic drugs. European journal of clinical pharmacology 75 12 1695 1704 20191200 10.1007/s00228-019-02756-4 31511938 TKS-/published_papers/35016879 谷本 幸多朗 日浅 雅博 天真 寛文 寺町 順平 Ashtar Mohannad 岩佐 昌美 小田 明日香 曾我部 公子 大浦 雅博 原田 武志 中村 信元 三木 浩和 遠藤 逸朗 田中 栄二 松本 俊夫 安倍 正博 不動性骨吸収の亢進は骨髄内の骨髄腫進展を促進させる (一社)日本骨代謝学会 日本骨代謝学会学術集会プログラム抄録集 1349-0761 37 188 188 20190900 TKS-/published_papers/35016872 天真 寛文 寺町 順平 日浅 雅博 谷本 幸多朗 アシテル・モハナッド アリウン・ザヤバット・エルデネ 岩佐 昌美 原田 武志 中村 信元 三木 浩和 遠藤 逸朗 田中 栄二 松本 俊夫 安倍 正博 TAK1阻害は関節リウマチにおけるNLRP3インフラマソーム誘導性の炎症および骨破壊を抑制する (一社)日本骨代謝学会 日本骨代謝学会学術集会プログラム抄録集 1349-0761 37 190 190 20190900 TKS-/published_papers/29516357 Hirokazu Miki Shingen Nakamura Masahiro Oura Hirofumi Hamano Kenji Ikuta Naoto Okada Yasunobu Okamoto Kimiko Sogabe Mamiko Takahashi Masami Iwasa Kengo Udaka Takeshi Harada Kiyoe Kurahashi Shiro Fujii Sumiko Yoshida Kumiko Kagawa Itsuro Endo Ken-Ichi Aihara Masahiro Abe Correlation between high serum alkaline phosphatase levels and denosumab-related hypocalcemia in patients with multiple myeloma. British journal of haematology 186 2 355 358 20190700 10.1111/bjh.15837 30859556 TKS-/published_papers/26880633 Ariunzaya Bat-Erdene Bat-Erdene A Shingen Nakamura Nakamura S Asuka Oda Oda A Masami Iwasa Iwasa M Jumpei Teramachi Teramachi J Mohannad Ashtar Ashtar M Takeshi Harada Harada T Hirokazu Miki Miki H Hirofumi Tenshin Tenshin H Masahiro Hiasa Hiasa M Shiro Fujii Fujii S Kimiko Sogabe Sogabe K Masahiro Oura Oura M Kengo Udaka Udaka K Kumiko Kagawa Kagawa K Sumiko Yoshida Yoshida S Ken-Ichi Aihara Aihara KI Kiyoe Kurahashi Kurahashi K Itsuro Endo Endo I Masahiro Abe Abe M Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-α and ATRA. British journal of haematology 0007-1048 185 5 969 974 20190600 10.1111/bjh.15673 30474853 TKS-/published_papers/35139242 Ashtar Mohannad 不動は骨吸収と骨髄腫進展を促進させる(Immobilization promotes bone resorption and tumor expansion in myeloma) (一社)日本骨髄腫学会 International Journal of Myeloma 2187-3143 9 1 88 88 20190500 TKS-/published_papers/35139236 Ashter Mohannd ROSの骨髄腫の骨病変と癌治療関連骨減少症の誘発における重要な役割(Critical roles of ROS in induction of bone disease and cancer treatment-induced bone loss in myeloma) (一社)日本骨髄腫学会 International Journal of Myeloma 2187-3143 9 1 90 90 20190500 TKS-/published_papers/35139231 多発性骨髄腫患者におけるPIM2，TAK1の重要性(PIM2 and phosphorylated TAK1 expression as important prognostic factors in patients with multiple myeloma) (一社)日本骨髄腫学会 International Journal of Myeloma 2187-3143 9 1 139 139 20190500 TKS-/published_papers/9470172 Masami Iwasa Takeshi Harada Asuka Oda Ariunzaya Bat-Erdene Jumpei Teramachi Hirofumi Tenshin Mohannad Ashtar Masahiro Oura Kimiko Sogabe Kengo Udaka Shiro Fujii Shiroh Fujii Shingen Nakamura Hirokazu Miki Kumiko Kagawa Shuji Ozaki Masahiro Abe PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ. Immunotherapy is revolutionizing the treatment paradigm for multiple myeloma (MM). Interferon (IFN)-γ is essential for immune responses, whereas immune checkpoint molecules, such as programmed cell death-1 ligand-1 (PD-L1), mitigate the beneficial anti-tumor immune responses. As HDAC inhibitors alter the immunogenicity and anti-tumor immune responses, we here explored the regulation of PD-L1 expression in MM cells by the clinically available HDAC inhibitor panobinostat in the presence of IFN-γ. IFN-γ activated the STAT1-IRF1 pathway to upregulate PD-L1 expression in MM cells, and panobinostat was able to upregulate their PD-L1 expression without activating the STAT1-IRF1 pathway. Of note, panobinostat enhanced IFN-γR1 expression, which substantially increased the total and phosphorylated levels of STAT1 protein but reduced IRF1 protein levels through proteasomal degradation in the presence of IFN-γ. Panobinostat further enhanced the IFN-γ-mediated durable STAT1 activation in MM cells; STAT1 gene silencing abolished the PD-L1 upregulation by panobinostat and IFN-γ in combination, indicating a critical role for STAT1. These results suggest that panobinostat enhances PD-L1 expression by facilitating the IFN-γ-STAT1 pathway in a ligand-dependent manner in MM cells with ambient IFN-γ. PD-L1 upregulation should be taken into account when combining immunotherapies with panobinostat. gene silencing abolished the PD-L1 upregulation by panobinostat and IFN-γ in combination, indicating a critical role for STAT1. These results suggest that panobinostat enhances PD-L1 expression by facilitating the IFN-γ-STAT1 pathway in a ligand-dependent manner in MM cells with ambient IFN-γ. PD-L1 upregulation should be taken into account when combining immunotherapies with panobinostat. Oncotarget 1949-2553 10 20 1903 1917 20190308 10.18632/oncotarget.26726 30956773 TKS-/published_papers/34979567 谷垣 雄都 山口 裕大 岡田 直人 中村 信元 賀川 久美子 藤井 志朗 三木 浩和 石澤 啓介 安倍 正博 佐藤 陽一 ゲノムワイド関連解析を用いたテイコプラニン・バンコマイシン投与による皮疹発現および血中濃度関連遺伝子座の同定 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 139 3 57 57 20190300 TKS-/published_papers/9470174 Seiji Kishi Fumiaki Obata Hirokazu Miki Motokazu Matsuura Kenji Nishimura Masanori Tamaki Fumi Kishi Taichi Murakami Hideharu Abe Kojiro Nagai Masahiro Abe Toshio Doi Lambda Light Chain Non-crystalline Proximal Tubulopathy with IgD Lambda Myeloma. Light Chain Proximal Tubulopathy (LCPT) is a rare form of paraprotein-related kidney disease in which monoclonal free light chains damage the proximal renal tubular epithelial cells. We herein report the case of a 78-year-old woman who presented with anemia and kidney dysfunction. Serum and urine protein electrophoresis analyses revealed a monoclonal IgD and λ free light chains. Proximal tubular injury and the accumulation of λ light chains were found by kidney biopsy. Electron microscopy revealed no organized structure suggestive of crystals. LCPT was caused by IgD lambda myeloma and bortezomib and dexamethasone therapy led to very good partial response (VGPR) without a worsening of the kidney function. Internal medicine (Tokyo, Japan) 1349-7235 57 24 3597 3602 20181215 10.2169/internalmedicine.1323-18 30101939 TKS-/published_papers/9470173 Yuko Miyakami 宮上 侑子 Shingen Nakamura 中村 信元 Masahiro Oura 大浦 雅博 Yasunobu Okamoto 岡本 惠暢 高橋 真美子 Kimiko Sogabe 曽我部 公子 岩佐 昌美 Takeshi Harada 原田 武志 Shiroh Fujii 藤井 志朗 Hirokazu Miki 三木 浩和 Kumiko Kagawa 賀川 久美子 Hisanori Uehara 上原 久典 Masahiro Abe 安倍 正博 不明熱と著明な高CRP血症で発症したde novo CD20陰性びまん性大細胞型B細胞リンパ腫の1例 Shikoku Acta Medica 四国医学雑誌 0037-3699 74 5-6 193 200 20181200 TKS-/published_papers/40807691 · · ROSの骨髄腫の骨病変と癌治療関連骨減少症の誘発における役割(Roles of ROS in induction of bone disease and cancer treatment-induced bone loss in myeloma) (一社)日本血液学会-東京事務局 臨床血液 1882-0824 59 9 1604 1604 20180900 TKS-/published_papers/40807685 Ariunzaya Bat-Erdene 骨髄腫細胞のTAK1過剰活性化とTAK1を介する骨髄腫進展と骨破壊の機序(Mechanisms of TAK1 activation in myeloma cells and TAK1-mediated myeloma growth and bone destruction) (一社)日本血液学会-東京事務局 臨床血液 1882-0824 59 9 1604 1604 20180900 TKS-/published_papers/40807678 · · TRAILによる骨髄腫細胞と破骨細胞のc-FLIPを介する生存経路の逆方向の制御(Inverse regulation of c-FLIP-mediated survival in myeloma cells and osteoclasts by TRAIL) (一社)日本血液学会-東京事務局 臨床血液 1882-0824 59 9 1605 1605 20180900 TKS-/published_papers/40807672 Ariunzaya Bat-Erdene Mohannad Ashtar カテプシンK阻害薬の骨細胞への効果と骨髄腫における骨形成作用(The effects of cathepsin K inhibition on osteocytes: its role in bone restoration in MM bone disease) (一社)日本血液学会-東京事務局 臨床血液 1882-0824 59 9 1611 1611 20180900 TKS-/published_papers/40807665 Mohannad Ashtar Ariunzaya Bat-Erdene 神経切断による麻痺と免荷の骨髄腫の進展への影響(Impact of denervation-induced paralysis and mechanical unloading on tumor expansion in myeloma) (一社)日本血液学会-東京事務局 臨床血液 1882-0824 59 9 1612 1612 20180900 TKS-/published_papers/25035412 Kishi S Obata F Miki H Matsuura M Nishimura K Tamaki M Kishi F Murakami T Abe H Nagai K Abe M Doi T A Case of Lambda Light Chain Non-crystalline Proximal Tubulopathy with IgD Lambda Myeloma. Internal medicine (Tokyo, Japan) 0918-2918 57 24 3597 3602 20180800 10.2169/internalmedicine.1323-18 30101939 TKS-/published_papers/40807703 日浅 雅博 寺町 順平 天真 寛文 谷本 幸多朗 Ashtar Mohannad Bat-Erdene Ariunzaya 岩佐 昌美 原田 武志 中村 信元 三木 浩和 遠藤 逸朗 田中 栄二 松本 俊夫 安倍 正博 カテプシンK阻害による多発性骨髄腫骨病変部の骨量回復プロセスにおける骨細胞の役割 (一社)日本骨代謝学会 日本骨代謝学会学術集会プログラム抄録集 1349-0761 36 146 146 20180700 TKS-/published_papers/9470175 Kumiko Kagawa Hikaru Fujino Hirokazu Miki Kimiko Sogabe Mamiko Takahashi Tomoko Maruhashi Kengo Udaka Masami Iwasa Shiro Fujii Shingen Nakamura Masahiro Abe Cryptosporidiosis in a transplant recipient with severe intractable diarrhea: Detection of Cryptosporidium oocysts by intestinal biopsies Blackwell Publishing Inc. Transplant Infectious Disease 1399-3062 20 2 e12826 e12826 20180401 10.1111/tid.12826 29277954 2-s2.0-85041047530 TKS-/published_papers/9470177 Hirokazu Miki Shingen Nakamura Asuka Oda Hirofumi Tenshin Jumpei Teramachi Masahiro Hiasa Ariunzaya Bat-Erdene Yusaku Maeda Masahiro Oura Mamiko Takahashi Masami Iwasa Takeshi Harada Shiro Fujii Kiyoe Kurahashi Sumiko Yoshida Kumiko Kagawa Itsuro Endo Kenichi Aihara Mariko Ikuo Kohji Itoh Koichiro Hayashi Michihiro Nakamura Masahiro Abe Effective impairment of myeloma cells and their progenitors by hyperthermia. Multiple myeloma (MM) remains incurable, and MM-initiating cells or MM progenitors are considered to contribute to disease relapse through their drug-resistant nature. In order to improve the therapeutic efficacy for MM, we recently developed novel superparamagnetic nanoparticles which selectively accumulate in MM tumors and extirpate them by heat generated with magnetic resonance. We here aimed to clarify the therapeutic effects on MM cells and their progenitors by hyperthermia. Heat treatment at 43°C time-dependently induced MM cell death. The treatment upregulated endoplasmic reticulum (ER) stress mediators, ATF4 and CHOP, while reducing the protein levels of Pim-2, IRF4, c-Myc and Mcl-1. Combination with the proteasome inhibitor bortezomib further enhanced ER stress to potentiate MM cell death. The Pim inhibitor SMI-16a also enhanced the reduction of the Pim-2-driven survival factors, IRF4 and c-Myc, in combination with the heat treatment. The heat treatment almost completely eradicated "side population" fractions in RPMI8226 and KMS-11 cells and suppressed their clonogenic capacity as determined by in vitro colony formation and tumorigenic capacity in SCID mice. These results collectively demonstrated that hyperthermia is able to impair clonogenic drug-resistant fractions of MM cells and enhance their susceptibility to chemotherapeutic drugs. Oncotarget 1949-2553 9 12 10307 10316 20180213 10.18632/oncotarget.23121 29535808 TKS-/published_papers/26977663 Shingen Nakamura Momoyo Azuma Tomoko Maruhashi Kimiko Sogabe Ryohei Sumitani Munenori Uemura Masami Iwasa Shiro Fujii Hirokazu Miki Kumiko Kagawa Takashi Hiraga Noriyasu Kondo Hiromi Fujita Fumihiko Mahara Masahiro Abe Steroid pulse therapy in patients with encephalopathy associated with severe fever with thrombocytopenia syndrome. Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne infectious disease caused by the SFTS virus (SFTSV). Clinical symptoms of SFTS often involve encephalopathy and other central neurological symptoms, particularly in seriously ill patients; however, pathogenesis of encephalopathy by SFTSV is largely unknown. Herein, we present case reports of three patients with SFTS, complicated by encephalopathy, admitted to Tokushima University hospital: one patient was a 63-year-old man, while the other two were 83- and 86-year-old women. All of them developed disturbance of consciousness around the 7th day post onset of fever. After methylprednisolone pulse therapy of 500 mg/day, all of them recovered without any neurological sequelae. SFTSV genome was not detected in the cerebrospinal fluid of 2 out of the 3 patients that were available for examination. In these patients, disturbance of consciousness seemed to be an indirect effect of the cytokine storm triggered by SFTSV infection. We propose that short-term glucocorticoid therapy might be beneficial in the treatment of encephalopathy during early phase of SFTSV infection. Journal of Infection and Chemotherapy 1437-7780 24 5 389 392 20180207 10.1016/j.jiac.2017.11.004 29428565 TKS-/published_papers/9470176 Jumpei Teramachi Masahiro Hiasa Asuka Oda Takeshi Harada Shingen Nakamura Ryota Amachi Hirofumi Tenshin Masami Iwasa Shiro Fujii Kumiko Kagawa Hirokazu Miki Kiyoe Kurahashi Sumiko Yoshida Itsuro Endo Tatsuji Haneji Toshio Matsumoto Masahiro Abe Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma. British journal of haematology 1365-2141 180 4 581 585 20180200 10.1111/bjh.14388 27748523 TKS-/published_papers/25105039 Fujii S Nakamura S Oda A Miki H Tenshin H Teramachi J Hiasa M Bat-Erdene A Maeda Y Oura M Takahashi M Iwasa M Endo I Yoshida S Aihara KI Kurahashi K Harada T Kagawa K Nakao M Sano S Abe M Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity. British journal of haematology 0007-1048 180 2 246 258 20180100 10.1111/bjh.15033 29327347 TKS-/published_papers/9470178 Hirofumi Tenshin Jumpei Teramachi Asuka Oda Ryota Amachi Masahiro Hiasa Ariunzaya Bat-Erdene Keiichiro Watanabe Masami Iwasa Takeshi Harada Shiro Fujii Kumiko Kagawa Kimiko Sogabe Shingen Nakamura Hirokazu Miki Kiyoe Kurahashi Sumiko Yoshida Kenichi Aihara Itsuro Endo Eiji Tanaka Toshio Matsumoto Masahiro Abe TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) agonists induce tumor-specific apoptosis indicating that they may be an attractive therapeutic strategy against cancers, including multiple myeloma (MM). Osteoclastogenesis is highly induced in MM, which in turn enhances MM growth, thereby forming a vicious cycle between MM tumor expansion and bone destruction. However, the effects of TRAIL on MM-enhanced osteoclastogenesis remain largely unknown. Here, we show that TRAIL induced apoptosis in MM cells, but not in osteoclasts (OCs), and that it rather facilitated receptor activator of NF-κB ligand-induced osteoclastogenesis along with upregulation of cellular FLICE inhibitory protein (c-FLIP). TRAIL did not induce death-inducing signaling complex formation in OCs, but formed secondary complex (complex II) with the phosphorylation of transforming growth factor β-activated kinase-1 (TAK1), and thus activated NF-κB signaling. c-FLIP knockdown abolished complex II formation, thus permitting TRAIL induction of OC cell death. The TAK1 inhibitor LLZ1640-2 abrogated the TRAIL-induced c-FLIP upregulation and NF-κB activation, and triggered TRAIL-induced caspase-8 activation and cell death in OCs. Interestingly, the TRAIL-induced caspase-8 activation caused enzymatic degradation of the transcription factor Sp1 to noticeably reduce c-FLIP expression, which further sensitized OCs to TRAIL-induced apoptosis. Furthermore, the TAK1 inhibition induced antiosteoclastogenic activity by TRAIL even in cocultures with MM cells while potentiating TRAIL's anti-MM effects. These results demonstrated that osteoclastic lineage cells use TRAIL for their differentiation and activation through tilting caspase-8-dependent apoptosis toward NF-κB activation, and that TAK1 inhibition subverts TRAIL-mediated NF-κB activation to resume TRAIL-induced apoptosis in OCs while further enhancing MM cell death in combination with TRAIL. Blood advances 2473-9529 1 24 2124 2137 20171114 10.1182/bloodadvances.2017008813 29296860 TKS-/published_papers/9470179 Kohei Muto Naoko Matsui Yuki Unai Waka Sakai Shotaro Haji Kengo Udaka Hirokazu Miki Takahiro Furukawa Masahiro Abe Ryuji Kaji Memory B cell resurgence requires repeated rituximab in myasthenia gravis Elsevier Ltd Neuromuscular Disorders 1873-2364 27 10 918 922 20171001 10.1016/j.nmd.2017.06.012 28694074 2-s2.0-85021854163 TKS-/published_papers/9470182 T. Harada H. Miki Q. Cui A. Oda R. Amachi J. Teramachi A. Bat-Erdene K. Sogabe M. Iwasa S. Fujii S. Nakamura K. Kagawa S. Yoshida I. Endo K. Aihara S. Ozaki T. Matsumoto M. Abe Expansion of Th 1 -like Vγ 9 Vδ 2 T cells by new-generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acid Nature Publishing Group Leukemia 1476-5551 31 1 258 262 20170101 10.1038/leu.2016.273 27698446 2-s2.0-84994111994 TKS-/published_papers/35444757 KAGAWA Kumiko 賀川 久美子 MAEDA Yusaku 前田 悠作 OURA Masahiro 大浦 雅博 SOGABE Kimiko 曽我部 公子 FUJINO Hikaru 藤野 ひかる TAKAHASHI Mamiko 髙橋 真美子 MARUHASHI Tomoko 丸橋 朋子 IWASA Masami 岩佐 昌美 UDAKA Kengo 宇高 憲吾 HARADA Takeshi 原田 武志 ISE Takayuki 伊勢 孝之 FUJII Shiro 藤井 志朗 NAKAMURA Shingen 中村 信元 MIKI Hirokazu 三木 浩和 YAGI Shusuke 八木 秀介 TAKEUCHI Kyoko 竹内 恭子 OZAKI Shuji 尾崎 修治 ABE Masahiro 安倍 正博 Analysis of long-term survivors with cardiac AL amyloidosis 治療後長期生存が得られた心不全合併ALアミロイドーシス症例の検討 <p>Cardiac AL amyloidosis (CA) is generally known as a severe disease with very poor prognosis. Here we retrospectively examined seven patients with CA in our cohort who achieved long-term survival. All six patients who underwent high-dose melphalan and autologous stem cell transplantation (ASCT) survived for >3 years, whereas four patients survived for >5 years. Patients who underwent ASCT had prompt hematological responses, and five patients showed organ responses. ASCT helps to achieve a quick and deep hematological response required for long-term survival in patients with CA. New agents have been implemented for the treatment of CA. However, the risks and benefits of each treatment modality should be considered according to patient condition, thus making the best use of ASCT in combination with new agents for the treatment of CA.</p> <p>ALアミロイドーシスは，多発性骨髄腫やMGUS(monoclonal gammopathy of undetermined significance)などのモノクローナルな形質細胞が産生する免疫グロブリン軽鎖および重鎖が，アミロイド線維として組織に沈着し，臓器障害を惹起する難治性疾患である．なかでも心アミロイドーシス(以下CA)は，心不全症状が出現してからは，無治療の場合極めて予後不良であるため，その管理・治療が重要である¹⁾．ALアミロイドーシスに対しては，自家末梢血幹細胞移植併用メルファラン大量療法(以下ASCT)の有効性が報告されているが，CAにおいては治療関連毒性が強く，その適応を慎重に検討する必要がある^{2, 3)}．近年，多発性骨髄腫において，ボルテゾミブ(Bor)や，免疫調節薬であるサリドマイド(Thal)やレナリドミド(Len)などの新規薬を用いた治療により，治療成績が向上している．ALアミロイドーシス症例においてもこれらの新規薬の有効性が示され，CAに対しても，重篤な有害事象の発生率が低く，有効であったとの報告がある^4∼6)．しかしながら，その長期の治療成績や予後については，十分な情報がない．そこで我々は，当科において治療し，長期生存が得られた心不全合併CA例について，後方視的に検討した．</p> The Japanese Society of Hematology 一般社団法人 日本血液学会 Rinsho Ketsueki 臨床血液 58 11 2197 2204 20170000 10.11406/rinketsu.58.2197 TKS-/published_papers/25608532 Shingen Nakamura Kumiko Kagawa Ryohei Sumitani Munenori Uemura Mamiko Takahashi Masami Iwasa Shiro Fujii Hirokazu Miki Masahiro Abe Primary CD30-positive Diffuse Large B-cell Lymphoma in the Superior Vena Cava INTERNAL MEDICINE 1349-7235 56 15 2043 2047 20170000 10.2169/internalmedicine.56.8203 28768978 TKS-/published_papers/9470180 Ariunzaya Bat-Erdene Hirokazu Miki Asuko Oda Shingen Nakamura Jumpei Teramachi Ryota Amachi Hirofumi Tenshin Masahiro Hiasa Masami Iwasa Takeshi Harada Shiro Fujii Kimiko Sogabe Kumiko Kagawa Sumiko Yoshida Itsuro Endo Kenichi Aihara Masahiro Abe Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors ONCOTARGET 1949-2553 7 48 79050 79061 20161100 10.18632/oncotarget.12594 27738323 TKS-/published_papers/9470181 Ryota Amachi Masahiro Hiasa Jumpei Teramachi Takeshi Harada Asuka Oda Shingen Nakamura Derek Hanson Keiichiro Watanabe Shiro Fujii Hirokazu Miki Kumiko Kagawa Masami Iwasa Itsuro Endo Takeshi Kondo Sumiko Yoshida Ken-ichi Aihara Kiyoe Kurahashi Yoshiaki Kuroda Hideaki Horikawa Eiji Tanaka Toshio Matsumoto Masahiro Abe A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alteration ONCOTARGET 1949-2553 7 43 70447 70461 20161000 10.18632/oncotarget.11927 27626482 TKS-/published_papers/25104781 Teramachi J Hiasa M Oda A Harada T Nakamura S Amachi R Tenshin H Iwasa M Fujii S Kagawa K Miki H Kurahashi K Yoshida S Endo I Haneji T Matsumoto T Abe M Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma. British journal of haematology 0007-1048 null null 20161000 10.1111/bjh.14388 27748523 TKS-/published_papers/9470184 Shingen Nakamura Hirokazu Miki Asuka Oda Ryota Amachi Jumpei Teramachi Kimiko Sogabe Hikaru Fujino Tomoko Maruhashi Shiroh Fujii Kumiko Kagawa Masahiro Abe Susceptibility to bendamustine considerably varies among myeloma cells, but is enhanced in acidic conditions International Journal of Myeloma 2187-3143 6 1 7 11 20151000 TKS-/published_papers/9470183 Derek James Hanson Shingen Nakamura Ryota Amachi Masahiro Hiasa Asuka Oda Daisuke Tsuji Kohji Itoh Takeshi Harada Kazuki Horikawa Jumpei Teramachi Hirokazu Miki Toshio Matsumoto Masahiro Abe Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation ONCOTARGET 1949-2553 6 32 33568 33586 20151000 10.18632/oncotarget.5598 26384349 TKS-/published_papers/9470188 M. Hiasa J. Teramachi A. Oda R. Amachi T. Harada S. Nakamura H. Miki S. Fujii K. Kagawa K. Watanabe I. Endo Y. Kuroda T. Yoneda D. Tsuji M. Nakao E. Tanaka K. Hamada S. Sano K. Itoh T. Matsumoto M. Abe Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma Nature Publishing Group Leukemia 1476-5551 29 1 207 217 20150110 10.1038/leu.2014.147 24787487 2-s2.0-84920689582 TKS-/published_papers/9470185 Hirokazu Miki Shingen Nakamura A Oda R Amachi Keiichiro Watanabe D Hanson Jumpei Teramachi Masahiro Hiasa H Yagi K Sogabe M Takahashi T Maruhashi K Udaka T Harada Shiroh Fujii A Nakano Kumiko Kagawa M Ri S Iida Shuji Ozaki T Matsumoto Masahiro Abe Induction of endoplasmic reticulum stress by bortezomib sensitizes myeloma cells to DR5-mediated cell death International Journal of Myeloma. 5 1 1 7 20150100 TKS-/published_papers/25911416 Hiasa M Teramachi J Oda A Amachi R Harada T Nakamura S Miki H Fujii S Kagawa K Watanabe K Endo I Kuroda Y Yoneda T Tsuji D Nakao M Tanaka E Hamada K Sano S Itoh K Matsumoto T Abe M Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma. Leukemia 0887-6924 29 1 207 217 20150100 10.1038/leu.2014.147 24787487 TKS-/published_papers/9470187 Kumiko Kagawa 賀川 久美子 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Masahiro Abe 安倍 正博 Successful treatment of refractory severe aplastic anemia with bone marrow transplantation from a genetically identical twin 同系骨髄移植が著効した最重症再生不良性貧血の1例 Shikoku Acta Medica 四国医学雑誌 0037-3699 70 3,4 77 80 20140600 TKS-/published_papers/9470189 Koichiro Hayashi Michihiro Nakamura Hirokazu Miki Shuji Ozaki Masahiro Abe Toshio Matsumoto Toshinari Kori Kazunori Ishimura Photostable iodinated silica/porphyrin hybrid nanoparticles with heavy-atom effect for wide-field photodynamic/photothermal therapy using single light source Advanced Functional Materials 1616-301X 24 4 503 513 20140129 10.1002/adfm.201301771 2-s2.0-84892950115 TKS-/published_papers/9470186 Koichiro Hayashi Michihiro Nakamura Hirokazu Miki Shuji Ozaki Masahiro Abe Toshio Matsumoto Wataru Sakamoto Toshinobu Yogo Kazunori Ishimura Magnetically Responsive Smart Nanoparticles for Cancer Treatment with a Combination of Magnetic Hyperthermia and Remote-Control Drug Release THERANOSTICS 1838-7640 4 8 834 844 20140000 10.7150/thno.9199 24955144 TKS-/published_papers/25028540 Koichiro Hayashi Michihiro Nakamura Hirokazu Miki Shuji Ozaki Masahiro Abe Toshio Matsumoto Toshinari Kori Kazunori Ishimura Photostable iodinated silica/porphyrin hybrid nanoparticles with heavy-atom effect for wide-field photodynamic/photothermal therapy using single light source Advanced Functional Materials 1616-301X 24 503 513 20140100 10.1002/adfm.201301771 2-s2.0-84892950115 TKS-/published_papers/9470191 Shingen Nakamura Hirokazu Miki Shinsuke Kido Ayako Nakano Masahiro Hiasa Asuka Oda Hiroe Amou Keiichiro Watanabe Takeshi Harada Shiro Fujii Kyoko Takeuchi Kumiko Kagawa Shuji Ozaki Toshio Matsumoto Masahiro Abe Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib International Journal of Hematology 0925-5710 98 1 66 73 20130700 10.1007/s12185-013-1367-z 23708974 2-s2.0-84880304849 TKS-/published_papers/25104800 Nakamura S Miki H Kido S Nakano A Hiasa M Oda A Amou H Watanabe K Harada T Fujii S Takeuchi K Kagawa K Ozaki S Matsumoto T Abe M Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib. International journal of hematology 0925-5710 98 1 66 73 20130700 10.1007/s12185-013-1367-z 23708974 TKS-/published_papers/26247627 Harada T Ozaki S Oda A Fujii S Nakamura S Miki H Kagawa K Takeuchi K Matsumoto T Abe M Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma. International journal of hematology 0925-5710 97 6 743 748 20130600 10.1007/s12185-013-1321-0 23609417 TKS-/published_papers/25028543 Koichiro Hayashi Michihiro Nakamura Hirokazu Miki Shuji Ozaki Masahiro Abe Toshio Matsumoto Kazunori Ishimura Gold nanoparticle cluster-plasmon-enhanced fluorescent silica core-shell nanoparticles for X-ray computed tomography-fluorescence dual-mode imaging of tumors Chemical Communications 1359-7345 49 5334 5336 20130600 10.1039/c3cc41876f 2-s2.0-84877733500 TKS-/published_papers/9470192 Koichiro Hayashi Michihiro Nakamura Hirokazu Miki Shuji Ozaki Masahiro Abe Toshio Matsumoto Kazunori Ishimura Gold Nanoparticle Cluster/Plasmon-Enhanced Fluorescent Silica Core-Shell Nanoparticles for X-Ray Computed Tomography/Fluorescence Dual-Mode Imaging of Tumors Owing to the surface plasmon resonance-enhanced electromagnetic field, clustered gold nanoparticles-fluorescent silica core-shell nanoparticles became excited within the therapeutic window and fluoresced strongly in this window. The nanoparticles enabled tumor detection using fluorescence imaging and X-ray computed tomography. Chemical Communications 1364-548X 49 5334 5336 20130423 10.1039/c3cc41876f 23648868 TKS-/published_papers/27247738 Takeshi Harada Shuji Ozaki Asuka Oda Shiro Fujii Shingen Nakamura Hirokazu Miki Kumiko Kagawa Kyoko Takeuchi Toshio Matsumoto Masahiro Abe Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma. Transient inflammatory reactions have been reported in a subpopulation of patients with multiple myeloma (MM) during lenalidomide (Len) plus dexamethasone (DEX) therapy. Here, we examined serum levels of Th1 (IL-2 and IFN-) and Th2 cytokines (IL-6 and TNF-) in nine refractory or relapsed MM patients treated with Len plus low-dose DEX. Six patients showed elevation of C-reactive protein (CRP) after the initiation of therapy. In these patients, IFN- and IL-6 were also elevated in two and three patients, respectively. The remaining three patients showed no appreciable changes in CRP or these cytokines. Furthermore, Len enhanced the production of both Th1 and Th2 cytokines in normal peripheral blood mononuclear cells and in patient bone marrow mononuclear cells containing primary myeloma cells and lymphocytes. These results suggest that the modulation of the Th1 and Th2 cytokine production by Len may contribute to transient inflammatory reaction in MM patients. International Journal of Hematology 1865-3774 97 6 743 748 20130423 10.1007/s12185-013-1321-0 23609417 TKS-/published_papers/9470193 Koichiro Hayashi Michihiro Nakamura Wataru Sakamoto Toshinobu Yogo Hirokazu Miki Shuji Ozaki Masahiro Abe Toshio Matsumoto Kazunori Ishimura Superparamagnetic nanoparticle clusters for cancer theranostics combining magnetic resonance imaging and hyperthermia treatment Theranostics 1838-7640 3 6 366 376 20130000 10.7150/thno.5860 23781284 2-s2.0-84882252518 TKS-/published_papers/9470190 Takeshi Harada Shuji Ozaki Asuka Oda Daisuke Tsuji Akishige Ikegame Masami Iwasa Kengo Udaka Shiro Fujii Shingen Nakamura Hirokazu Miki Kumiko Kagawa Yoshiaki Kuroda Shigeto Kawai Kohji Itoh Hisafumi Yamada-Okabe Toshio Matsumoto Masahiro Abe Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors. The immunomodulatory drug lenalidomide (Len) has drawn attention to potentiate antibody-dependent cellular cytotoxicity (ADCC)-mediated immunotherapies. We developed the defucosylated version (YB-AHM) of humanized monoclonal antibody against HM1.24 (CD317) overexpressed in multiple myeloma (MM) cells. In this study, we evaluated ADCC by YB-AHM and Len in combination against MM cells and their progenitors. YB-AHM was able to selectively kill via ADCC MM cells in bone marrow samples from patients with MM with low effector/target ratios, which was further enhanced by treatment with Len. Interestingly, Len also up-regulated HM1.24 expression on MM cells in an effector-dependent manner. HM1.24 was found to be highly expressed in a drug-resistant clonogenic "side population" in MM cells; and this combinatory treatment successfully reduced SP fractions in RPMI 8226 and KMS-11 cells in the presence of effector cells, and suppressed a clonogenic potential of MM cells in colony-forming assays. Collectively, the present study suggests that YB-AHM and Len in combination may become an effective therapeutic strategy in MM, warranting further study to target drug-resistant MM clonogenic cells. PloS one 1932-6203 8 12 e83905 e83905 20130000 10.1371/journal.pone.0083905 24386306 TKS-/published_papers/9470194 Koichiro Hayashi Michihiro Nakamura Hirokazu Miki Shuji Ozaki Masahiro Abe Toshio Matsumoto Kazunori Ishimura Near-infrared fluorescent silica/porphyrin hybrid nanorings for in vivo cancer imaging Advanced Functional Materials 1616-301X 22 17 3539 3546 20120911 10.1002/adfm.201200219 2-s2.0-84865725654 TKS-/published_papers/25911422 Ikegame A Ozaki S Tsuji D Harada T Fujii S Nakamura S Miki H Nakano A Kagawa K Takeuchi K Abe M Watanabe K Hiasa M Kimura N Kikuchi Y Sakamoto A Habu K Endo M Itoh K Yamada-Okabe H Matsumoto T Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors. Leukemia 0887-6924 26 9 2124 2134 20120900 10.1038/leu.2012.78 22430632 TKS-/published_papers/25028546 Koichiro Hayashi Michihiro Nakamura Hirokazu Miki Shuji Ozaki Masahiro Abe Toshio Matsumoto Kazunori Ishimura Near-infrared fluorescent silica/porphyrin hybrid nanorings for in vivo cancer imaging Advanced Functional Materials 1616-301X 22 3539 3546 20120900 10.1002/adfm.201200219 2-s2.0-84865725654 TKS-/published_papers/25104825 Nakano A Miki H Nakamura S Harada T Oda A Amou H Fujii S Kagawa K Takeuchi K Ozaki S Matsumoto T Abe M Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate. Journal of bioenergetics and biomembranes 0145-479X 44 1 31 38 20120200 10.1007/s10863-012-9412-9 22298254 TKS-/published_papers/25104822 Kagawa K Nakano A Miki H Oda A Amou H Takeuchi K Nakamura S Harada T Fujii S Yata K Ozaki S Matsumoto T Abe M Inhibition of TACE activity enhances the susceptibility of myeloma cells to TRAIL. PloS one 7 2 e31594 null 20120000 10.1371/journal.pone.0031594 22389670 TKS-/published_papers/25911251 Nakano Ayako Abe Masahiro Tsuji Daisuke Miki Hirokazu Ikegame Akishige Nakamura Shingen Harada Takeshi Fujii Shiro Kagawa Kumiko Takeuchi Kyoko Ozaki Shuji Itoh Kohji Matsumoto Toshio Inhibition of Hexokinase II Inactivates ABC Transporters and Restores Drug Sensitivity in Myeloma Cells BLOOD 0006-4971 118 21 65 66 20111118 TKS-/published_papers/9470195 Hirokazu Miki Shuji Ozaki Shingen Nakamura Asuka Oda Hiroe Amou Akishige Ikegame Keiichiro Watanabe Masahiro Hiasa Qu Cui Takeshi Harada Shiro Fujii Ayako Nakano Kumiko Kagawa Kyoko Takeuchi Ken-ichiro Yata Akira Sakai Masahiro Abe Toshio Matsumoto KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts British Journal of Haematology 0007-1048 155 3 328 339 20111100 10.1111/j.1365-2141.2011.08844.x 21902681 2-s2.0-80053987418 TKS-/published_papers/25104836 Miki H Ozaki S Nakamura S Oda A Amou H Ikegame A Watanabe K Hiasa M Cui Q Harada T Fujii S Nakano A Kagawa K Takeuchi K Yata K Sakai A Abe M Matsumoto T KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts. British journal of haematology 0007-1048 155 3 328 339 20111100 10.1111/j.1365-2141.2011.08844.x 21902681 TKS-/published_papers/26599047 J. Asano A. Nakano A. Oda H. Amou M. Hiasa K. Takeuchi H. Miki S. Nakamura T. Harada S. Fujii K. Kagawa I. Endo K. Yata A. Sakai S. Ozaki T. Matsumoto M. Abe The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells LEUKEMIA 0887-6924 25 7 1182 1188 20110700 10.1038/leu.2011.60 21475253 TKS-/published_papers/25104840 Cui Q Shibata H Oda A Amou H Nakano A Yata K Hiasa M Watanabe K Nakamura S Miki H Harada T Fujii S Kagawa K Takeuchi K Ozaki S Matsumoto T Abe M Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells. International journal of hematology 0925-5710 94 1 63 70 20110700 10.1007/s12185-011-0885-9 21698356 TKS-/published_papers/26977633 Qu Cui Hironobu Shibata Asuka Oda Hiroe Amou Ayako Nakano Kenichiro Yata Masahiro Hiasa Keiichiro Watanabe Shingen Nakamura Hirokazu Miki Takeshi Harada Shiroh Fujii Kumiko Kagawa Kyoko Takeuchi Shuji Ozaki Toshio Matsumoto Masahiro Abe Targeting myeloma-osteoclast interaction with V9V2 T cells. Multiple myeloma (MM) cells stimulate osteoclastogenesis, and osteoclasts (OCs) in turn enhance MM growth and drug resistance, resulting in a vicious cycle. V9V2 T cells exert potent anti-tumor effects, making T cell-based immunotherapies using these cells attractive candidates for currently incurable malignancies, such as MM. However, the impact of such treatments on the MM-OC interaction is largely unknown. We demonstrate here that V9V2 T cells expanded by zoledronic acid and IL-2 exerted potent cytotoxic effects on both MM cells and OCs, even in coculture settings, but showed no such effect on bone marrow stromal cells. V9V2 T cells marginally affected colony formation from normal hematopoietic progenitors, and furthermore migrated toward osteopontin and MIP-1, factors produced by the MM-OC interaction. These results suggest that V9V2 T cells expanded by zoledronic acid and IL-2 are able to migrate to MM bone lesions and preferentially target OCs as well as MM cells, thereby inhibiting both tumor expansion and bone destruction. International Journal of Hematology 1865-3774 94 1 63 70 20110623 10.1007/s12185-011-0885-9 21698356 TKS-/published_papers/25104845 Nakano A Abe M Oda A Amou H Hiasa M Nakamura S Miki H Harada T Fujii S Kagawa K Takeuchi K Watanabe T Ozaki S Matsumoto T Delayed treatment with vitamin C and N-acetyl-L-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib. International journal of hematology 0925-5710 93 6 727 735 20110600 10.1007/s12185-011-0850-7 21526377 TKS-/published_papers/25104852 Ozaki S Harada T Fujii S Nakamura S Miki H Nakano A Kagawa K Takeuchi K Abe M Matsumoto T Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma. International journal of hematology 0925-5710 93 2 257 259 20110200 10.1007/s12185-011-0775-1 21279817 TKS-/published_papers/25104831 Nakano A Tsuji D Miki H Cui Q El Sayed SM Ikegame A Oda A Amou H Nakamura S Harada T Fujii S Kagawa K Takeuchi K Sakai A Ozaki S Okano K Nakamura T Itoh K Matsumoto T Abe M Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells. PloS one 6 11 e27222 null 20110000 10.1371/journal.pone.0027222 22073292 TKS-/published_papers/25104864 Nakamura S Yata K Jinno T Harada T Fujii S Miki H Nakano A Kagawa K Takeuchi K Ozaki S Abe M Matsumoto T [Multiple myeloma complicated with disseminated zygomycosis after bortezomib therapy]. [Rinsho ketsueki] The Japanese journal of clinical hematology 0485-1439 51 8 690 695 20100800 10.11406/rinketsu.51.690 20805677 TKS-/published_papers/25104878 Takeuchi K Abe M Hiasa M Oda A Amou H Kido S Harada T Tanaka O Miki H Nakamura S Nakano A Kagawa K Yata K Ozaki S Matsumoto T Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PloS one 5 3 e9870 null 20100300 10.1371/journal.pone.0009870 20360846 TKS-/published_papers/25911257 Ikegame Akishige Ozaki Shuji Tsuji Daisuke Harada Takeshi Nakamura Shingen Miki Hirokazu Nakano Ayako Kagawa Kumiko Takeuchi Kyoko Yata Kenichiro Abe Masahiro Itoh Kohji Matsumoto Toshio A Recombinant HLA Class I-Specific Single-Chain Fv Diabody Can Target Cancer Stem Cell-Like Side Population Cells in Multiple Myeloma. BLOOD 0006-4971 114 22 1095 null 20091120 TKS-/published_papers/25104890 Miki H Ozaki S Tanaka O Lee E Takimoto T Watanabe H Fujii S Nakamura S Kagawa K Takeuchi K Yata K Abe M Kagami S Matsumoto T Marked improvement of platelet transfusion refractoriness after bortezomib therapy in multiple myeloma. International journal of hematology 0925-5710 89 2 223 226 20090300 10.1007/s12185-009-0255-z 19225725 TKS-/published_papers/27410853 Shuji Ozaki Osamu Tanaka Shiro Fujii Yuri Shigekiyo Hirokazu Miki Masahito Choraku Kumiko Kagawa Jin Asano Kyoko Takeuchi Ken-ichi Kitazoe Toshihiro Hashimoto Masahiro Abe Toshio Matsumoto Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma INTERNATIONAL JOURNAL OF HEMATOLOGY 1865-3774 86 2 180 185 20070800 10.1532/IJH97.07030 17875535 TKS-/misc/52670502 HARADA Takeshi 小田明日香 大口裕人 井上雄介 前田悠作 住谷龍平 大浦雅博 曽我部公子 八木ひかる 藤井志朗 中村信元 三木浩和 賀川久美子 尾崎修治 安倍正博 松岡賢市 Nuclear sequestration of ADAR1 p150 elicit ZBP1mediated apoptosis in myeloma cells by IFN-α ADAR1 p150の細胞質移行阻害はインターフェロンαによる骨髄腫細胞のZBP1介在アポトーシスを惹起する International Journal of Myeloma (Web) 2187-3143 15 3 null null 20250000 TKS-/misc/40807529 Takeshi Harada Yusuke Inoue Hirofumi Tenshin Asuka Oda Ryohei Sumitani Masahiro Oura Kimiko Sogabe Shiro Fujii Shingen Nakamura Hirokazu Miki Masahiro Hiasa Jumpei Teramachi Masahiro Abe Novel strategy of elotuzumab and zoledronic acid with Th1-like gamma delta Tcells against myeloma CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2152-2669 21 S41 S42 20211000 TKS-/misc/52421160 曽我部公子 中村信元 藤井志朗 三木浩和 小田明日香 原田武志 住谷龍平 大浦雅博 賀川久美子 天真寛文 寺町順平 李政樹 飯田真介 安倍正博 プロテアソーム阻害薬による骨髄腫細胞の抗アポトーシス因子PIM2の急速な蓄積 日本血液学会学術集会抄録(Web) 82nd null null 20200000 TKS-/misc/35016825 谷本幸多朗 谷本幸多朗 日浅雅博 日浅雅博 天真寛文 天真寛文 清水宗 清水宗 ASHTER Mohannad ASHTER Mohannad 比嘉佳基 比嘉佳基 寺町順平 原田武志 中村信元 三木浩和 遠藤逸朗 田中栄二 松本俊夫 安倍正博 不動は骨吸収と骨髄腫進展を促進させる 日本骨代謝学会学術集会プログラム抄録集(CD-ROM) 1349-0761 38th null null 20200000 TKS-/misc/35016819 天真寛文 天真寛文 アシテルモハナッド 寺町順平 日浅雅博 谷本幸多朗 清水宗 比嘉佳基 原田武志 大浦雅博 曽我部公子 中村信元 三木浩和 遠藤逸朗 田中栄二 松本俊夫 安倍正博 抗腫瘍薬が誘導するROSは破骨細胞分化を促進する:Xanthine oxidase阻害剤febuxostatの治療効果 日本骨代謝学会学術集会プログラム抄録集(CD-ROM) 1349-0761 38th null null 20200000 TKS-/misc/35016809 日浅雅博 日浅雅博 谷本幸多朗 谷本幸多朗 比嘉佳基 比嘉佳基 天真寛文 天真寛文 曽我部公子 大浦雅博 原田武志 中村信元 三木浩和 遠藤逸朗 松本俊夫 安倍正博 骨髄腫の破骨細胞-樹状細胞分化異常におけるTACE-TIMP-3系の重要な役割 日本血液学会学術集会抄録(Web) 82nd null null 20200000 TKS-/misc/35016802 原田武志 井上雄介 天真寛文 小田明日香 大浦雅博 曽我部公子 住谷龍平 藤井志朗 中村信元 三木浩和 賀川久美子 日浅雅博 寺町順平 安倍正博 エロツズマブの多面的な抗骨髄腫作用:γδT細胞および破骨細胞への影響 日本血液学会学術集会抄録(Web) 82nd null null 20200000 TKS-/misc/40807534 Takeshi Harada Asuka Oda Hiroto Ohguchi Yohann Grondin Hirofumi Tenshin Masahiro Hiasa Jumpei Teramachi Masahiro Oura Kimiko Sogabe Shiro Fujii Shingen Nakamura Hirokazu Miki Kumiko Kagawa Shuji Ozaki Teru Hideshima Kenneth C. Anderson Masahiro Abe Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma BLOOD 1528-0020 134 null null 20191100 10.1182/blood-2019-127679 TKS-/misc/25894001 土師 正太郎 佐光 亘 村上 永尚 大崎 裕亮 岡本 恵暢 曽我部 公子 宇高 憲吾 藤井 志朗 三木 浩和 安倍 正博 和泉 唯信 右上肢麻痺を呈し，PET-CTにて腕神経叢浸潤を認めた悪性リンパ腫の1例 (一社)日本神経学会 臨床神経学 0009-918X 59 8 550 550 20190800 TKS-/misc/35016837 天真寛文 天真寛文 寺町順平 寺町順平 日浅雅博 日浅雅博 谷本幸多朗 谷本幸多朗 ASHTAR Mohannad ASHTAR Mohannad ARIUNZAYA Bat Erdene 岩佐昌美 原田武志 中村信元 三木浩和 遠藤逸朗 田中栄二 松本俊夫 安倍正博 TAK1阻害は関節リウマチにおけるNLRP3インフラマソーム誘導性の炎症および骨破壊を抑制する 日本骨代謝学会学術集会プログラム抄録集 1349-0761 37th null null 20190000 TKS-/misc/35016922 Hirofumi Tenshin Jumpei Teramachi Masahiro Hiasa Asuka Oda Mohannad Ashtar Kotaro Tanimoto Iwasa Masami Ariunzaya Bat-Erdene Takeshi Harada Singen Nakamura Hirokazu Miki Itsuro Endo Eiji Tanaka Toshio Matsumoto Masahiro Abe Opposite effects of TRAIL on the Sp1-c-FLIP survival pathway in myeloma cells and osteoclasts. JOURNAL OF BONE AND MINERAL RESEARCH 1523-4681 33 341 341 20181100 TKS-/misc/35016910 Jumpei Teramachi Hirofumi Tenshin Masahiro Hiasa Asuka Oda Ariunzaya Bat-Erdene Takeshi Harada Shingen Nakamura Hirokazu Miki Itsuro Endo Toshio Matsumoto Masahiro Abe Disruption of a progressive vicious cycle between myeloma tumor growth and bone destruction by TAK1 inhibition JOURNAL OF BONE AND MINERAL RESEARCH 1523-4681 33 342 342 20181100 TKS-/misc/26598878 日浅雅博 日浅雅博 寺町順平 寺町順平 天真寛文 天真寛文 谷本幸多朗 谷本幸多朗 ASHTAR Mohannad ASHTAR Mohannad BAT‐ERDENE Ariunzaya 岩佐昌美 原田武志 中村信元 三木浩和 遠藤逸朗 田中栄二 松本俊夫 安倍正博 カテプシンK阻害による多発性骨髄腫骨病変部の骨量回復プロセスにおける骨細胞の役割 (一社)日本骨代謝学会 日本骨代謝学会学術集会プログラム抄録集 1349-0761 36th 146 146 20180700 TKS-/misc/26977653 大浦 雅博 三木 浩和 前田 悠作 高橋 真美子 岩佐 昌美 原田 武志 藤井 志朗 中村 信元 賀川 久美子 安倍 正博 田口 愛弓 別宮 浩文 石橋 直子 原 朋子 尾崎 敬治 後藤 哲也 柏原 秀也 周術期ガイドラインに基づき安全に胃切除が施行できた胃癌合併PNH症例 症例は69歳女性で，58歳頃より夜間早朝の赤色尿やLDH上昇などの溶血所見が出現し，発作性夜間ヘモグロビン尿症と診断された．骨粗鬆症による多発骨折をきたし近医に入院していた際，急激に貧血が進行し黒色便を認めた．上部消化管内視鏡検査にて胃角部小彎前壁に進行胃癌を認め，手術目的に当院消化器外科へ転院した．腹腔鏡下幽門側胃切除術を施行する方針となり，周術期コントロールとしてエクリズマブ投与，抗凝固療法，ハプトグロビン投与を行った．術前に尿路感染症を発症したが抗生剤で速やかに改善し，術中術後には溶血発作を認めず，血栓症の増悪もきたすことなく術後経過は良好であった．プレドニゾロンを投与していたが，縫合不全や感染症などの合併症もなく転院した． (株)メディカルレビュー社 PNH Frontier 2188-4552 5 52 55 20180600 TKS-/misc/26977655 前田 悠作 原田 武志 中村 信元 賀川 久美子 大浦 雅博 岩佐 昌美 藤井 志朗 三木 浩和 安倍 正博 菌状息肉症から移行した中枢神経症状を呈する治療抵抗性セザリー症候群に対してforodesineが有効であった1例 (一社)日本血液学会-東京事務局 臨床血液 0485-1439 59 5 632 633 20180500 TKS-/misc/26977650 原田 武志 小田 明日香 寺町 順平 Bat-Erdene Ariunzaya 岩佐 昌美 前田 悠作 中村 信元 大浦 雅博 藤井 志朗 三木 浩和 賀川 久美子 秀島 輝 Anderson Kenneth C 安倍 正博 HDAC1/3阻害はIRF4-Pim-2経路を抑制し抗骨髄腫作用を惹起する 日本骨髄腫学会 International Journal of Myeloma 8 2 106 106 20180500 TKS-/misc/26977647 岩佐 昌美 原田 武志 Bat-Erdene Ariunzaya 小田 明日香 前田 悠作 高橋 真美子 大浦 雅博 寺町 順平 藤井 志朗 中村 信元 三木 浩和 賀川 久美子 安倍 正博 パノビスタットによる骨髄腫細胞のIFN-γ-STAT1-PD-L1経路の増強 日本骨髄腫学会 International Journal of Myeloma 8 2 107 107 20180500 TKS-/misc/26977644 三木 浩和 中村 信元 大浦 雅博 前田 悠作 高橋 真美子 岩佐 昌美 原田 武志 藤井 志朗 賀川 久美子 遠藤 逸朗 粟飯原 賢一 安倍 正博 高ALP血症は骨病変を有する骨髄腫患者のデノスマブ関連低カルシウム血症の発症予測因子である 日本骨髄腫学会 International Journal of Myeloma 8 2 131 131 20180500 TKS-/misc/25892787 中野睦基 中野睦基 大浦雅博 前田悠作 細井美希 原倫世 山上紘規 高橋真美子 原田武志 藤井志朗 中村信元 賀川久美子 安倍正博 三木浩和 川端豊 伊勢孝之 上原久典 遊離免疫グロブリン軽鎖の測定が診断と早期治療介入に有用であったALアミロイドーシスの1例 徳島医学会 四国医学雑誌 0037-3699 74 1-2 85 85 20180425 TKS-/misc/40964686 八木ひかる 八木ひかる 三木浩和 曽我部公子 曽我部公子 前田悠作 大浦雅博 高橋真美子 宇高憲吾 岩佐昌美 原田武志 藤井志朗 中村信元 賀川久美子 高尾正一郎 安倍正博 私のこの一枚(164)血友病Aに合併した急性出血性胆嚢炎 血液フロンティア 1344-6940 28 2 131-134 null 20180130 10.20837/5201802131 TKS-/misc/26598853 天真寛文 天真寛文 寺町順平 寺町順平 日浅雅博 日浅雅博 谷本幸多朗 谷本幸多朗 MOHANNAD Ashtar MOHANNAD Ashtar ARIUNZAYA Bat Erdene 岩佐昌美 原田武志 中村信元 三木浩和 遠藤逸朗 田中栄二 松本俊夫 安倍正博 TAK1阻害はTRAILによる壊骨細胞活性化作用を遮断させると同時にTRAILの抗骨髄腫作用を増強する 日本骨代謝学会学術集会プログラム抄録集 1349-0761 36th 177 null 20180000 TKS-/misc/28015451 Jumpei Teramachi Masahiro Hiasa Asuka Oda Hirofumi Tenshin Ryota Amachi Takeshi Harada Shingen Nakamura Hirokazu Miki Itsuro Endo Tatsuji Haneji Toshio Matsumoto Masahiro Abe TAK1 inhibition impairs myeloma cell-bone marrow interaction to reduce myeloma tumor growth and bone destruction. JOURNAL OF BONE AND MINERAL RESEARCH 1523-4681 32 S65 S65 20171200 TKS-/misc/26977659 山口 純代 住田 智志 中村 信元 前田 悠作 大浦 雅博 高橋 真美子 岩佐 昌美 原田 武志 藤井 志朗 賀川 久美子 安倍 正博 三木 浩和 リウマチ様関節炎に対する免疫抑制療法中に発症した成人T細胞性白血病/リンパ腫の1例 徳島医学会 四国医学雑誌 0037-3699 73 5-6 334 335 20171200 TKS-/misc/26598906 天真寛文 寺町順平 小田明日香 天知良太 日浅雅博 渡邉佳一郎 ARIUNZAYA Baterdene 岩佐昌美 藤井志朗 賀川久美子 中村信元 三木浩和 遠藤逸朗 田中栄二 松本俊夫 安倍正博 TRAILは破骨細胞を活性化させるが,TAK1阻害により骨髄腫細胞とともに破骨細胞にもTRAILのアポトーシス誘導活性が惹起できる (一社)日本骨代謝学会 日本骨代謝学会学術集会プログラム抄録集 1349-0761 35th 205 205 20170700 TKS-/misc/27118281 山口裕大 佐藤陽一 谷垣雄都 岡田直人 中村信元 賀川久美子 藤井志朗 三木浩和 石澤啓介 石澤啓介 安部正博 山内あい子 バンコマイシン投与による副作用発現及び血中濃度とCYP遺伝子多型との関連解析 日本医薬品情報学会総会・学術大会講演要旨集 20th 181 null 20170600 TKS-/misc/26266539 大森理央 佐藤陽一 木口美沙妃 岡田直人 中村信元 賀川久美子 藤井志郎 三木浩和 石澤啓介 石澤啓介 安部正博 山内あい子 ビンクリスチンによる副作用発現とMDR1遺伝子多型との関連性 日本医薬品情報学会総会・学術大会講演要旨集 20th 181 null 20170600 TKS-/misc/25892804 上田浩之 上田浩之 上村宗範 住谷龍平 高橋真美子 岩佐昌美 藤井志朗 中村信元 賀川久美子 安倍正博 三木浩和 松立吉弘 坂東良美 上原久典 常山幸一 篠原正幸 全トランス型レチノイン酸による寛解導入療法中に発熱,咽頭・陰部潰瘍,全身性紅斑を来した急性前骨髄球性白血病の1例 徳島医学会 四国医学雑誌 0037-3699 73 1-2 148-149 149 20170425 TKS-/misc/26598895 天真寛文 天真寛文 寺町順平 寺町順平 小田明日香 天知良太 天知良太 日浅雅博 日浅雅博 渡邉佳一郎 渡邉佳一郎 ARIUNZAYA Baterdene 岩佐昌美 藤井志朗 賀川久美子 中村信元 三木浩和 遠藤逸朗 田中栄二 松本俊夫 安倍正博 TAK1阻害はTRAILの抗骨髄腫作用を増強するとともに骨吸収促進活性を抑制活性に変換する 日本骨髄腫学会 International Journal of Myeloma (Web) 2187-3143 7 1 ROMBUNNO.O1-6 (WEBONLY)59 20170400 TKS-/misc/26598782 天真 寛文 寺町 順平 小田 明日香 天知 良太 日浅 雅博 渡邉 佳一郎 Ariunzaya Baterdene 岩佐 昌美 藤井 志朗 賀川 久美子 中村 信元 三木 浩和 遠藤 逸朗 田中 栄二 松本 俊夫 安倍 正博 TAK1阻害はTRAILの抗骨髄腫作用を増強するとともに骨吸収促進活性を抑制活性に変換する 日本骨髄腫学会 International Journal of Myeloma 7 1 59 59 20170400 TKS-/misc/28023808 T. Harada H. Miki Q. Cui A. Oda R. Amachi J. Teramachi A. Bat-Erdene K. Sogabe M. Iwasa S. Fujii S. Nakamura K. Kagawa S. Yoshida I. Endo K. Aihara S. Ozaki T. Matsumoto M. Abe Expansion of Th-1-like V gamma V-9 delta T-2 cells by new-generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acid LEUKEMIA 1476-5551 31 1 258 262 20170100 10.1038/leu.2016.273 TKS-/misc/28114688 Hirokazu Miki Takeshi Harada Qu Cui Asuka Oda Ariunzaya Bat-Erdene Hirofumi Tenshin Ryota Amachi Ryohei Sumitani Munenori Uemura Mamiko Takahashi Masami Iwasa Shiro Fujii Jumpei Teramachi Shingen Nakamura Kumiko Kagawa Shuji Ozaki Masahiro Abe Expansion of gamma delta T Cells By New Generation IMiDs and Their Cytotoxicity Against Myeloma Progenitors BLOOD 1528-0020 128 22 null null 20161200 TKS-/misc/26598918 天真寛文 天真寛文 寺町順平 小田明日香 天知良太 天知良太 日浅雅博 渡辺佳一郎 渡辺佳一郎 中村信元 三木浩和 遠藤逸朗 田中栄二 松本俊夫 安倍正博 破骨細胞はTAK1の発現誘導を介しアポトーシスを抑制しTRAILにより成熟活性化される (一社)日本骨代謝学会 日本骨代謝学会学術集会プログラム抄録集 1349-0761 34th 183 183 20160700 TKS-/misc/26598889 寺町 順平 日浅 雅博 小田 明日香 天眞 寛文 天知 良太 原田 武志 渡邉 佳一郎 中村 信元 三木 浩和 遠藤 逸郎 羽地 達次 松本 俊夫 安倍 正博 骨髄腫腫瘍進展と骨破壊病変形成におけるTAK-1-Pim-2経路の役割 (一社)日本骨代謝学会 日本骨代謝学会学術集会プログラム抄録集 1349-0761 34 183 183 20160700 TKS-/misc/26598884 渡邉 佳一郎 寺町 順平 天知 良太 小田 明日香 天真 寛文 日浅 雅博 中村 信元 三木 浩和 遠藤 逸朗 川谷 誠 長田 裕之 田中 栄二 松本 俊夫 安倍 正博 リベロマイシンAによる酸性環境での骨髄腫細胞の治療抵抗性の克服 (一社)日本骨代謝学会 日本骨代謝学会学術集会プログラム抄録集 1349-0761 34 183 183 20160700 TKS-/misc/28118409 J. Teramachi M. Hiasa A. Oda H. Tenshin R. Amachi T. Harada S. Nakamura H. Miki I. Endo T. Haneji T. Matsumoto M. Abe THERAPEUTIC IMPACT OF TAK-1 INHIBITION ON TUMOR GROWTH AND BONE DESTRUCTION IN MYELOMA HAEMATOLOGICA 0390-6078 101 162 162 20160600 TKS-/misc/26598928 寺町順平 寺町順平 日浅雅博 日浅雅博 小田明日香 原田武志 天眞寛文 天眞寛文 中村信元 天知良太 天知良太 藤井志郎 渡邉佳一郎 渡邉佳一郎 賀川久美子 三木浩和 遠藤逸郎 羽地達次 松本俊夫 安倍正博 Pim‐2は骨髄腫の破骨細胞形成促進に必須のRANKL下流媒介因子である 日本骨髄腫学会 International Journal of Myeloma (Web) 2187-3143 6 2 ROMBUNNO.P-18 (WEBONLY)90 20160400 TKS-/misc/26598923 天真寛文 天真寛文 寺町順平 寺町順平 小田明日香 天知良太 天知良太 日浅雅博 日浅雅博 渡辺佳一郎 渡辺佳一郎 中村信元 三木浩和 遠藤逸朗 田中栄二 松本俊夫 安倍正博 TRAILはTAK1を介し破骨細胞の活性化・生存を促進する 日本骨髄腫学会 International Journal of Myeloma (Web) 2187-3143 6 2 ROMBUNNO.P-59 (WEBONLY)131 20160400 TKS-/misc/26977668 Masahiro Abe Hirokazu Miki Shingen Nakamura Multiple myeloma [Rinshō ketsueki] The Japanese journal of clinical hematology 0485-1439 57 260 269 20160301 10.11406/rinketsu.57.260 27076236 2-s2.0-84983000091 TKS-/misc/26598847 天眞寛文 天眞寛文 寺町順平 小田明日香 天知良太 天知良太 BAT‐ERDENE Ariunzaya 日浅雅博 渡邉佳一郎 渡邉佳一郎 中村信元 三木浩和 遠藤逸朗 田中栄二 松本俊夫 安倍正博 破骨細胞系細胞はアポトーシス誘導因子TRAILを生存促進・破骨細胞形成誘導因子として利用する:TAK1‐Pim‐2経路の役割 癌と骨病変研究会抄録集 19th 22 null 20160000 TKS-/misc/26598799 Teramachi Jumpei Hiasa Masahiro Oda Asuka Tenshin Hirofumi Amachi Ryota Harada Takeshi Hanson Derek Watanabe Keiichiro Fujii Shiro Kagawa Kumiko Nakamura Shingen Miki Hirokazu Endo Itsuro Ozaki Shuji Matsumoto Toshio Abe Masahiro Pim Inhibition Suppresses Osteoclastogenesis and Tumor Growth in Myeloma BLOOD 0006-4971 126 23 null null 20151203 TKS-/misc/26977666 ABE Masahiro 安倍 正博 MIKI Hirokazu 三木 浩和 NAKAMURA Shingen 中村 信元 Management of bone disease in myeloma patients: zoledronic acid or denosumab? 骨髄腫骨病変の管理:ゾレドロン酸かデノスマブか 一般社団法人 日本血液学会 Rinsho Ketsueki 臨床血液 0485-1439 56 8 997 1004 20150801 10.11406/rinketsu.56.997 26345558 2-s2.0-84956595241 TKS-/misc/26598944 天真 寛文 寺町 順平 小田 明日香 天知 良太 日浅 雅博 渡邉 佳一郎 中村 信元 三木 浩和 遠藤 逸朗 田中 栄二 松本 俊夫 安倍 正博 アポトーシス誘導因子TRAILによる破骨細胞分化・生存の促進 (一社)日本骨代謝学会 日本骨代謝学会学術集会プログラム抄録集 1349-0761 33 164 164 20150700 TKS-/misc/26598939 寺町 順平 日浅 雅博 小田 明日香 天眞 寛文 天知 良太 中村 信元 三木 浩和 遠藤 逸朗 羽地 達次 松本 俊夫 安倍 正博 骨髄腫腫瘍進展と骨破壊病変形成におけるTAK-1の枢軸的役割 (一社)日本骨代謝学会 日本骨代謝学会学術集会プログラム抄録集 1349-0761 33 164 164 20150700 TKS-/misc/26598934 寺町順平 日浅雅博 小田明日香 天眞寛文 天知良太 中村信元 三木浩和 遠藤逸朗 羽地達次 松本俊夫 安倍正博 Pim阻害による骨髄腫骨病変の治療:破骨細胞形成の抑制 (一社)日本骨代謝学会 日本骨代謝学会学術集会プログラム抄録集 1349-0761 33rd 165 165 20150700 TKS-/misc/26598913 天知 良太 日浅 雅博 寺町 順平 小田 明日香 渡邉 佳一郎 天真 寛文 中村 信元 三木 浩和 近藤 剛 遠藤 逸朗 田中 栄二 松本 俊夫 安倍 正博 酸性環境での骨髄腫細胞のTRPV1の発現亢進と酸環境への適応 (一社)日本骨代謝学会 日本骨代謝学会学術集会プログラム抄録集 1349-0761 33 165 165 20150700 TKS-/misc/26598951 寺町順平 日浅雅博 小田明日香 原田武志 天眞寛文 天知良太 三木浩和 中村信元 藤井志朗 賀川久美子 遠藤逸朗 松本俊夫 安倍正博 Pim阻害による骨髄腫骨吸収亢進の抑制 日本骨髄腫学会 Int J Myeloma (Web) 2187-3143 5 2 O-61 (WEBONLY)102 20150500 TKS-/misc/26598858 寺町順平 日浅雅博 小田明日香 原田武志 天知良太 天眞寛文 中村信元 三木浩和 藤井志朗 賀川久美子 遠藤逸朗 松本俊夫 安倍正博 TAK‐1は骨髄腫腫瘍進展と骨破壊病変形成の枢軸的な媒介因子である Int J Myeloma (Web) 2187-3143 5 2 O-30 (WEBONLY)null 20150000 TKS-/misc/26599042 Ryota Amachi Masahiro Hiasa Jumpei Teramachi Keiichiro Watanabe Takeshi Harada Shiro Fujii Shingen Nakamura Hirokazu Miki Asuka Oda Eiji Tanaka Itsuro Endo Toshio Matsumoto Masahiro Abe Acid sensing and survival signaling in myeloma cells in acidic bone lesions: formation of acid-induced vicious cycle. JOURNAL OF BONE AND MINERAL RESEARCH 1523-4681 29 S372 S373 20140200 TKS-/misc/26599031 Jumpei Teramachi Masahiro Hiasa Asuka Oda Ryota Amachi Takeshi Harada Shingen Nakamura Kumiko Kagawa Hirokazu Miki Shiro Fujii Keiichiro Watanabe Itsuro Endo Toshio Matsumoto Masahiro Abe Critical role of Pim-2 in NF-kappa B-mediated suppression of osteoblastogenesis and stimulation of osteoclastogenesis: Therapeutic impact of Pim inhibition on myeloma bone disease. JOURNAL OF BONE AND MINERAL RESEARCH 1523-4681 29 S63 S64 20140200 TKS-/misc/52719428 原田武志 三木浩和 CUI Qu 中村信元 小田明日香 高橋真美子 岩佐昌美 宇高憲吾 藤井志朗 賀川久美子 尾崎修治 林幸壱郎 中村教泰 田中義正 松本俊夫 安倍正博 骨髄腫前駆細胞を標的としたレナリドミドにより増幅されるTh1様γδT細胞療法の効果 International Journal of Myeloma (Web) 2187-3143 4 2 null null 20140000 TKS-/misc/35356046 Kobayashi Seiji 小林 誠司 Kitaoka Atsunori 北岡 豊永 Sogabe Kimiko 曽我部 公子 Yagi Hikaru 八木 ひかる Maruhashi Tomoko 丸橋 朋子 Takahashi Mamiko 高橋 真美子 Utaka Kengo 宇高 憲吾 Fujii Shiro 藤井 志朗 Nakamura Shingen 中村 信元 Kagawa Kumiko 賀川 久美子 Miki Hirokazu 三木 浩和 Abe Masahiro 安倍 正博 O-30 About the current state of our hospital in peripheral blood stem cell collection with Spectra Optia(Oral Session 8) O-30 Spectra Optiaを用いたPBSCCにおける当院の現状について(方法・技術・装置(1),一般演題8,第35回日本アフェレシス学会学術大会) 日本アフェレシス学会 日本アフェレシス学会雑誌 1340-5888 33 167 167 20140000 TKS-/misc/26598865 天知良太 日浅雅博 寺町順平 小田明日香 DEREK Hanson 中村信元 三木浩和 渡邉佳一郎 遠藤逸郎 田中栄二 松本俊夫 安倍正博 酸が惹起する骨髄腫細胞の酸感受と生存シグナルの悪循環 癌と骨病変研究会抄録集 17th 26 null 20140000 TKS-/misc/28212788 Takeshi Harada Qu Cui Shingen Nakamura Hirokazu Miki Asuka Oda Ryota Amachi Masami Iwasa Kengo Udaka Shiro Fujii Kumiko Kagawa Shuji Ozaki Yoshimasa Tanaka Toshio Matsumoto Masahiro Abe Robust Induction Of Th1-Like gamma delta T Cells With Anti-Myeloma Activity By Lenalidomide In Combination With HMB-PP As Well As Zoledronic Acid BLOOD 1528-0020 122 21 null null 20131100 TKS-/misc/26598815 Watanabe Keiichiro Abe Masahiro Mori Hiroshi Amachi Ryota Hiasa Masahiro Harada Takeshi Fujii Shiro Nakamura Shingen Miki Hirokazu Kagawa Kumiko Endo Itsuro Tanaka Eiji Matsumoto Toshio Potent induction of bone formation in myeloma bone lesions by the cathepsin K inhibitor KK1-300-01 in combination with the proteasome inhibitor bortezomib JOURNAL OF BONE AND MINERAL RESEARCH 0884-0431 28 null null 20130200 TKS-/misc/26598806 Amachi Ryota Amachi Ryota Abe Masahiro Hiasa Masahiro Watanabe Keiichiro Fujii Shiro Harada Takeshi Miki Hirokazu Nakamura Shingen Endo Itsuro Tanaka Eiji Matsumoto Toshio Acidic conditions epigenetically repress the TRAIL receptor DR4 in myeloma cells to confer their resistance to TRAIL JOURNAL OF BONE AND MINERAL RESEARCH 0884-0431 28 null null 20130200 TKS-/misc/26598821 Fujii Shiro Iwasa Masami Harada Takeshi Nakamura Shingen Miki Hirokazu Nakano Ayako Kagawa Kumiko Amachi Ryota Watanabe Keiichiro Hiasa Masahiro Ozaki Shuji Matsumoto Toshio Abe Masahiro Targeting Drug-Resistant Myeloma Cells in an Acidic Milieu by Pim Inhibition BLOOD 0006-4971 120 21 null null 20121116 TKS-/misc/37362995 尾崎 修治 原田 武志 三木 浩和 Forum 第2回中四国血液疾患治療研究会 ケースカンファレンス EBER陽性でIVL様の組織所見を呈したprimary cutaneous gamma-delta T-cell lymphomaの1例 メディカルレビュー社 Trends in hematological malignancies 1883-9053 4 1 58 60,5 20120300 TKS-/misc/28318014 Takeshi Harada Shuji Ozaki Asuka Oda Hiroe Amou Shiro Fujii Shingen Nakamura Hirokazu Miki Ayako Nakano Kumiko Kagawa Kyoko Takeuchi Masahiro Abe Hironobu Shibata Shigeto Kawai Hisafumi Yamada-Okabe Toshio Matsumoto Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Significantly Enhances Myeloma Cell Cytotoxicity Via Antibody-Dependent Cellular Cytotoxicity BLOOD 0006-4971 118 21 799 799 20111100 TKS-/misc/28321742 M. Hiasa M. Abe A. Nakano K. Watanabe C. Qu T. Harada S. Fujii H. Miki S. Nakamura K. Kagawa K. Takeuchi E. Tanaka K. Asaoka S. Ozaki T. Matsumoto DUAL EFFECTS OF PIM INHIBITION ON MYELOMA: INDUCTION OF BONE FORMATION AND TUMOR SUPPRESSION OSTEOPOROSIS INTERNATIONAL 0937-941X 22 S536 S537 20110900 TKS-/misc/28264223 Masahiro Abe Shiro Fujii Kyoko Takeuchi Shuji Ozaki Makoto Kawatani Hiroyuki Osada Eiji Tanaka Toshio Matsumoto Keiichiro Watanabe Cui Qu Masahiro Hiasa Ayako Nakano Takeshi Harada Shingen Nakamura Hirokazu Miki Kumiko Kagawa AN ACIDIC MICROENVIRONMENT ENHANCES MYELOMA GROWTH BUT TRIGGERS ANTI-TUMOR AND ANTIRESORPTIVE ACTIVITY OF REVEROMYCIN A OSTEOPOROSIS INTERNATIONAL 0937-941X 22 22 22 20110300 TKS-/misc/26599050 Masahiro Abe Shiro Fujii Kyoko Takeuchi Shuji Ozaki Makoto Kawatani Hiroyuki Osada Eiji Tanaka Toshio Matsumoto Keiichiro Watanabe Cui Qu Masahiro Hiasa Ayako Nakano Takeshi Harada Shingen Nakamura Hirokazu Miki Kumiko Kagawa AN ACIDIC MICROENVIRONMENT ENHANCES MYELOMA GROWTH BUT TRIGGERS ANTI-TUMOR AND ANTI-RESORPTIVE ACTIVITY OF REVEROMYCIN A OSTEOPOROSIS INTERNATIONAL 0937-941X 22 182 182 20110300 TKS-/misc/28309093 M. Abe M. Hiasa A. Nakano S. Nakamura H. Miki C. Qu K. Watanabe T. Harada K. Kagawa K. Takeuchi S. Ozaki T. Matsumoto TIMP-3 up-regulation facilitates osteoclastogenesis and suppresses DC differentiation from monocytes in the bone marrow microenvironment in myeloma BONE 8756-3282 48 1 S18 S18 20110100 10.1016/j.bone.2010.10.047 TKS-/misc/28284118 K. Watanabe M. Abe C. Qu M. Kawatani M. Hiasa A. Nakano T. Harad S. Nakamura H. Miki K. Kagawa K. Takeuchi H. Ozaki H. Osada E. Tanaka T. Matsumoto The novel anti-resorptive agent reveromycin A ameliorates bone destruction and tumor growth in myeloma BONE 8756-3282 48 1 S36 S37 20110100 10.1016/j.bone.2010.10.102 TKS-/misc/26598826 Cui Qu Abe Masahiro Miki Hirokazu Nakamura Shingen Watanabe Keiichiro Ikegame Akishige Hiasa Masahiro Nakano Ayako Harada Takeshi Fujii Shiro Kagawa Kumiko Takeuchi Kyoko Ozaki Shuji Matsumoto Toshio Lenalidomide In Combination with Zoledronic Acid Restores the Activation and,Anti-Myeloma Effects of gamma delta T Cells Attenuated by the Bone Marrow Microenvironment. BLOOD 0006-4971 116 21 1246 null 20101119 TKS-/misc/26598810 Watanabe Keiichiro Abe Masahiro Cui Qu Kawatani Makoto Hiasa Masahiro Nakano Ayako Jinno Tadashi Harada Takeshi Fujii Shiro Nakamura Shingen Miki Hirokazu Kagawa Kumiko Takeuchi Kyoko Ozaki Shuji Tanaka Eiji Osada Hiroyuki Matsumoto Toshio An Acidic Milieu Created In Myeloma-Osteoclast Interaction Enhances Tumor Growth, but Triggers Anti-Myeloma Activity of Reveromycin A, a Novel Anti-Resorptive Agent BLOOD 0006-4971 116 21 203 204 20101119 TKS-/misc/26598984 中村信元 安倍正博 崔衢 渡邊佳一郎 池亀彰茂 日浅雅博 三木浩和 中野綾子 小田明日香 天羽宏枝 神野雅 原田武志 藤井志朗 賀川久美子 竹内恭子 尾崎修治 松本俊夫 ボルテゾミブによる骨芽細胞分化の促進は過剰な小胞体ストレスによって抑制される (一社)日本骨代謝学会 日本骨代謝学会学術集会プログラム抄録集 1349-0761 28th 237 237 20100700 TKS-/misc/26598977 日浅雅博 安倍正博 中野綾子 小田明日香 天羽宏枝 竹内恭子 賀川久美子 中村信元 三木浩和 矢田健一郎 渡辺佳一郎 尾崎修治 浅岡憲三 田中栄二 松本俊夫 骨髄間質細胞は単球のTACE活性を抑制し樹状細胞分化を抑制し破骨細胞分化を誘導する (一社)日本骨代謝学会 日本骨代謝学会学術集会プログラム抄録集 1349-0761 28th 204 204 20100700 TKS-/misc/26598831 Nakamura Shingen Abe Masahiro Cui Qu Nakano Ayako Oda Asuka Amou Hiroe Ikegame Akishige Harada Takeshi Hiasa Masahiro Miki Hirokazu Kagawa Kumiko Takeuchi Kyoko Yata Kenichiro Ozaki Shuji Matsumoto Toshio Facilitation of Osteoblast Differentiation by ATF-4 Accumulation through Proteasome Inhibition. BLOOD 0006-4971 114 22 724 null 20091120 TKS-/misc/26598993 中野綾子 安倍正博 日浅雅博 中村信元 三木浩和 賀川久美子 浅野仁 竹内恭子 矢田健一郎 遠藤逸朗 尾崎修治 松本俊夫 骨病変部微小環境はPim‐2の発現誘導を介し骨髄腫細胞の生存を促進する (一社)日本骨代謝学会 日本骨代謝学会学術集会プログラム抄録集 1349-0761 27th 239 239 20090700 TKS-/misc/26598989 中村信元 安倍正博 日浅雅博 三木浩和 中野綾子 賀川久美子 竹内恭子 矢田健一郎 尾崎修治 松本俊夫 プロテアソーム阻害薬による小胞体ストレス蛋白ATF4の蓄積は骨芽細胞分化を促進させる (一社)日本骨代謝学会 日本骨代謝学会学術集会プログラム抄録集 1349-0761 27th 194 194 20090700 TKS-/misc/26598834 Yata Kenichiro Abe Masahiro Oda Asuka Amou Hiroe Hiasa Masahiro Takeuchi Kyoko Nakamura Shingen Tanaka Osamu Miki Hirokazu Nakano Ayako Kagawa Kumiko Ozaki Shuji Matsumoto Toshio Anti-Myeloma Effects of gamma delta T Cells Are Hampered by Bone Marrow Stromal Cells but Resumed by Stromal Cell-Derived Osteoblasts. BLOOD 0006-4971 112 11 595 null 20081116 TKS-/misc/29131153 Hirokazu Miki Shuji Ozaki Osamu Tanaka Shingen Nakamura Ayako Nakano Kumiko Kagawa Kyoko Takeuchi Kenichiro Yata Masahiro Abe Toshio Matsumoto KRN5500, a Spicamycin Derivative, Exerts Anti-Myeloma Effects through Impairing Both Myeloma Cells and Osteoclasts BLOOD 0006-4971 112 11 589 589 20081100 TKS-/misc/26598997 竹内恭子 安倍正博 日浅雅博 田中修 中村信元 三木浩和 賀川久美子 矢田健一郎 尾崎修治 松本俊夫 骨髄腫骨病変部由来TGF‐βは脂肪細胞分化を抑制し骨髄内に間質細胞を誘導する (一社)日本骨代謝学会 日本骨代謝学会学術集会プログラム抄録集 1349-0761 26th 190 190 20081000 TKS-/misc/26598973 日浅 雅博 安倍 正博 竹内 恭子 矢田 健一郎 賀川 久美子 三木 浩和 尾崎 修治 浅岡 憲三 松本 俊夫 骨髄間質細胞は単球のM-CSFR発現を増強し単球由来樹状細胞分化を抑制し骨髄腫細胞による破骨細胞分化を促進する (一社)日本骨代謝学会 日本骨代謝学会学術集会プログラム抄録集 1349-0761 26 190 190 20081000 TKS-/misc/26599007 矢田健一郎 安倍正博 日浅雅博 竹内恭子 田中修 中村信元 三木浩和 賀川久美子 尾崎修治 松本俊夫 骨髄腫細胞と間質細胞の共存はM‐CSF受容体の発現増強を介し単球分化を破骨細胞側に偏らせる (一社)日本血液学会-東京事務局 臨床血液 0485-1439 49 9 931 931 20080930 TKS-/misc/26599003 竹内恭子 安倍正博 日浅雅博 田中修 中村信元 三木浩和 賀川久美子 矢田健一郎 尾崎修治 松本俊夫 骨髄腫骨病変部由来TGF‐βによる間質細胞からの脂肪細胞分化の抑制 (一社)日本血液学会-東京事務局 臨床血液 0485-1439 49 9 931 931 20080930 TKS-/misc/40964669 K. Takeuchi M. Abe M. Hiasa O. Tanaka S. Nakamura H. Miki K. Kagawa K. Yata T. Hashimoto S. Ozaki S. Kido T. Matsumoto TGF-beta Suppresses Adipocytic Differentiation and Enhances Accumulation of Stromal Cells in Myeloma Bone Lesions JOURNAL OF BONE AND MINERAL RESEARCH 0884-0431 23 S189 S189 20080900 TKS-/misc/29153243 M. Abe M. Hiasa A. Oda H. Amou K. Takeuchi O. Tanaka S. Nakamura H. Miki K. Kagawa K. Yata S. Ozaki S. Kido T. Matsumoto Bone Marrow Stromal Cells Up-regulate M-CSF Receptor in Monocytes to Disrupt Dendritic Cell Differentiation While Facilitating Osteoclastogenesis in Myeloma. JOURNAL OF BONE AND MINERAL RESEARCH 0884-0431 23 S301 S301 20080900 TKS-/misc/26599016 竹内恭子 安倍正博 日浅雅博 田中修 藤井志朗 中村信元 三原愛 三木浩和 浅野仁 賀川久美子 北添健一 矢田健一郎 橋本年弘 尾崎修治 木戸慎介 松本俊夫 TGF‐β阻害薬による骨芽細胞分化誘導は骨髄腫腫瘍増殖を抑制する (一社)日本血液学会-東京事務局 臨床血液 0485-1439 48 9 872 872 20070930 TKS-/misc/26599012 浅野仁 安部正博 日浅雅博 中村信元 三原愛 三木浩和 賀川久美子 竹内恭子 北添健一 矢田健一郎 橋本年弘 尾崎修治 松本俊夫 破骨細胞は骨髄腫細胞にPim‐2の発現を誘導し,骨髄腫細胞の生存を促進する (一社)日本血液学会-東京事務局 臨床血液 0485-1439 48 9 871 871 20070930 TKS-/misc/40964667 K. Takeuchi M. Abe A. Oda H. Amou M. Hiasa O. Tanaka S. Fujii S. Nakamura A. Mihara H. Miki J. Asano K. Kagawa K. Kitazoe K. Yata T. Hashimoto S. Ozaki S. Kido T. Matsumoto TGF-beta inhibition suppresses myeloma cell growth via enhancement of osteoblast differentiation JOURNAL OF BONE AND MINERAL RESEARCH 0884-0431 22 S295 S295 20070900 TKS-/misc/28777384 M. Abe M. Hiasa S. Kido A. Oda H. Amou S. Fujii O. Tanaka A. Mihara H. Miki J. Asano K. Kagawa K. Takeuchi K. Kitazoe T. Hashimoto S. Ozaki T. Matsumoto Up-regulation of tace in monocytes disrupts myeloma cell-induced osteoclastogenesis and induces myeloid dendritic cell differentiation HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 0390-6078 92 6 133 133 20070600 TKS-/misc/28775983 K. Takeuchi M. Abe A. Oda H. Amou S. Fujii O. Tanaka M. Hiasa A. Mihara H. Miki J. Asano K. Kagawa K. Kitazoe T. Hashimoto S. Ozaki S. Kido T. Matsumoto TGF-bera inhibition restores bone formation to suppress tumor growth in myeloma HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 0390-6078 92 6 133 133 20070600 TKS-/misc/26599021 竹内恭子 安倍正博 日浅雅博 田中修 藤井志朗 三原愛 三木浩和 浅野仁 賀川久美子 北添健一 橋本年弘 尾崎修治 木戸慎介 松本俊夫 骨芽細胞分化の誘導による骨髄腫細胞の増殖抑制 (一社)日本骨代謝学会 日本骨代謝学会学術集会プログラム抄録集 1349-0761 25th 199 199 20070600 TKS-/presentations/18027853 小田 直輝 李 悦子 松本 真弓 高松 典道 Hirokazu Miki 三木 浩和 Toshio Matsumoto 松本 俊夫 輸血後7日目にIgG抗E抗体を酵素法にて強く検出した一症例 第45回中四国支部医学検査学会 21211000 TKS-/presentations/18027753 Takeshi Harada Asuka Oda Hirofumi Tenshin Jumpei Teramachi Masahiro Oura Kimiko Sogabe Shiroh Fujii Shingen Nakamura Hirokazu Miki Kumiko Kagawa Shuji Ozaki Teru Hideshima C. Kenneth Anderson Masahiro Abe Targeting myeloma metabolisms regulated by HDAC1-IRF4 axis can be a novel therapeutic strategy 17th International Myeloma Workshop 20190913 TKS-/presentations/18027782 Yuto Tanigaki 谷垣 雄都 Yuta Yamaguchi 山口 裕大 Naoto Okada 岡田 直人 Shingen Nakamura 中村 信元 Kumiko Kagawa 賀川 久美子 Shiroh Fujii 藤井 志朗 Hirokazu Miki 三木 浩和 Keisuke Ishizawa 石澤 啓介 Masahiro Abe 安倍 正博 Youichi Sato 佐藤 陽一 ゲノムワイド関連解析を用いたテイコプラニン・バンコマイシン投与による皮疹発現および血中濃度関連遺伝子座の同定 日本薬学会 第139年会 20190321 TKS-/presentations/18027754 Mohannad Ashtar Hirofumi Tenshin Jumpei Teramachi Masahiro Hiasa Kotaro Tanimoto Oda Asuka Iwasa Masami Takeshi Harada Bat-Erdene Ariunzaya Kimiko Sogabe Masahiro Oura Shiroh Fujii Kumiko Kagawa Shingen Nakamura Hirokazu Miki Toshio Matsumoto Masahiro Abe Eiji Tanaka Peri-implantitis and the role of Febuxostat in osteoclast differentiation. AEEDC Dubai World Orthodontic Conference 20190206 TKS-/presentations/18027783 Yohsuke Kaneko 金子 遥祐 Mayo Kondou 近藤 真代 Naoki Takahashi 橋 直希 Makoto Tobiume 飛梅 亮 Hirokazu Ogino 荻野 広和 Seidai Satou 佐藤 正大 Hirokazu Miki 三木 浩和 Hisatsugu Goto 後東 久嗣 Masahiro Abe 安倍 正博 Yasuhiko Nishioka 西岡 安彦 多発小結節影を認めたHIV陽性ニューモシスチス肺炎の1例 第119回日本内科学会四国地方会 20181202 TKS-/presentations/18027755 Takeshi Harada Asuka Oda Yohann Grondin Jumpei Teramachi Ariunzaya Bat-Erdene Masami Iwasa Masahiro Oura Shingen Nakamura Kumiko Kagawa Yasunobu Okamoto Kimiko Sogabe Shiroh Fujii Hirokazu Miki Shuji Ozaki Teru Hideshima Kenneth C. Anderson Masahiro Abe The critical role of the HDAC1-IRF4-Pim-2 axis in myeloma cell growth and survival: therapeutic impacts of targeting the HDAC1-IRF4-Pim-2 axis 60th ASH Annual Meeting & Exposition 20181201 TKS-/presentations/18027756 Shingen Nakamura Hirokazu Miki Ariunzaya Bat-Erdene Yasunobu Okamoto Kimiko Sogabe Masahiro Oura Mamiko Takahashi Masami Iwasa Takeshi Harada Shiroh Fujii Kumiko Kagawa Masahiro Abe Alteration of muscle mass after chemotherapy in patients with newly diagnosed multiple myeloma. Esmo asia 2018 20181124 TKS-/presentations/18027785 Yuta Yamaguchi 山口 裕大 Yuto Tanigaki 谷垣 雄都 Naoto Okada 岡田 直人 Shingen Nakamura 中村 信元 Kumiko Kagawa 賀川 久美子 Shiroh Fujii 藤井 志朗 Hirokazu Miki 三木 浩和 Keisuke Ishizawa 石澤 啓介 Masahiro Abe 安倍 正博 Youichi Sato 佐藤 陽一 CYP遺伝子多型とバンコマイシンの副作用発現及び血中濃度との関連解析 第57回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会 20181110 TKS-/presentations/18027784 Rio Ohmori 大森 理央 Naoto Okada 岡田 直人 Shingen Nakamura 中村 信元 Kumiko Kagawa 賀川 久美子 Shiroh Fujii 藤井 志朗 Hirokazu Miki 三木 浩和 Keisuke Ishizawa 石澤 啓介 Masahiro Abe 安倍 正博 Youichi Sato 佐藤 陽一 ゲノムワイド関連解析を用いたビンクリスチンによる末梢神経障害発現関連遺伝子の同定 第57回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会 20181110 TKS-/presentations/18027786 Jumpei Teramachi Hirofumi Tenshin Masahiro Hiasa Oda Asuka Bat-Erdene Ariunzaya Takeshi Harada Iwasa Masami Shiroh Fujii Kimiko Sogabe Shingen Nakamura Hirokazu Miki Masahiro Oura Kumiko Kagawa Itsuro Endo Toshio Matsumoto Masahiro Abe Mechanisms of TAK1 over-activation in myeloma cells and TAK1-mediated myeloma growth and bone destruction 第80回日本血液学会学術集会 20181013 TKS-/presentations/18027791 Masahiro Hiasa Jumpei Teramachi Hirofumi Tenshin Kotaro Tanimoto Ariunzaya Bat-Erdene Mohannad Ashtar Masami Iwasa Takeshi Harada Shingen Nakamura Hirokazu Miki Kimiko Sogabe Oura Masahiro Shiroh Fujii Kumiko Kagawa Oda Asuka Itsuro Endo Eiji Tanaka Toshio Matsumoto Masahiro Abe The effects of cathepsin K inhibition on osteocytes: its role in bone restoration in MM bone disease. Japanese Society of Hematology The 80th Annual Meeting of the Japanese Society of Hematology 20181012 TKS-/presentations/18027790 Kotaro Tanimoto Masahiro Hiasa Hirofumi Tenshin Jumpei Teramachi Oda Asuka Mohannad Ashtar Ariunzaya Bat-Erdene Iwasa Masami Kimiko Sogabe Oura Masahiro Takeshi Harada Shingen Nakamura Hirokazu Miki Itsuro Endo Eiji Tanaka Toshio Matsumoto Masahiro Abe Impact of denervation-induced paralysis and mechanical unloading on tumor expansion in myeloma. Japanese Society of Hematology The 80th Annual Meeting of the Japanese Society of Hematology 20181012 TKS-/presentations/18027789 Hirofumi Tenshin Jumpei Teramachi Masahiro Hiasa Kotaro Tanimoto Mohannad Ashtar Ariunzaya Bat-Erdene Iwasa Masami Takeshi Harada Shingen Nakamura Hirokazu Miki Kimiko Sogabe Oura Masahiro Shiroh Fujii Kumiko Kagawa Itsuro Endo Eiji Tanaka Toshio Matsumoto Masahiro Abe Inverse regulation of c-FLIP-mediated survival in myeloma cells and osteoclasts by TRAIL. Japanese Society of Hematology The 80th Annual Meeting of the Japanese Society of Hematology 20181012 TKS-/presentations/18027788 Ashtar Mohannad Hirofumi Tenshin Jumpei Teramachi Masahiro Hiasa Kotaro Tanimoto Oda Asuka Iwasa Masami Takeshi Harada Ariunzaya Erdene Bat Kimiko Sogabe Oura Masahiro Shiroh Fujii Kumiko Kagawa Shingen Nakamura Hirokazu Miki Eiji Tanaka Toshio Matsumoto Masahiro Abe Roles of ROS in induction of bone disease and cancer treatment-induced bone loss in myeloma. Japanese Society of Hematology The 80th Annual Meeting of the Japanese Society of Hematology 20181012 TKS-/presentations/18027787 Masami Iwasa 岩佐 昌美 Takeshi Harada 原田 武志 Bat-Erdene Ariunzaya Ariunzaya Bat-Erdene 小田 明日香 Kimiko Sogabe 曽我部 公子 Masahiro Oura 大浦 雅博 Jumpei Teramachi 寺町 順平 Shiroh Fujii 藤井 志朗 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Kumiko Kagawa 賀川 久美子 Masahiro Abe 安倍 正博 HDAC阻害による骨髄腫細胞のIFN-γ-STAT1- PD-L1経路の増強効果 第80回日本血液学会学術集会 20181012 TKS-/presentations/18027758 Hirofumi Tenshin Jumpei Teramachi Masahiro Hiasa Oda Asuka Ashtar Mohannad Kotaro Tanimoto Iwasa Masami Bat-Erdene Ariunzaya Takeshi Harada Shingen Nakamura Hirokazu Miki Itsuro Endo Eiji Tanaka Toshio Matsumoto Masahiro Abe Opposite effects of TRAIL on the Sp-1-c-FLIP survival pathway in myeloma cells and osteoclasts. The American Society for Bone and Mineral Research ASBMR 2018 Annual Meeting 20180928 TKS-/presentations/18027757 Jumpei Teramachi Hirofumi Tenshin Masahiro Hiasa Oda Asuka Bat-Erdene Ariunzaya Takeshi Harada Shingen Nakamura Hirokazu Miki Itsuro Endo Toshio Matsumoto Masahiro Abe Disruption of a progressive vicious cycle between myeloma tumor growth and bone destruction by TAK1 inhibition ASBMR 2018 Annual Meeting 20180928 TKS-/presentations/18027759 Takeshi Harada Oda Asuka Jumpei Teramachi Bat-Erdene Ariunzaya Iwasa Masami Oura Masahiro Shingen Nakamura Kumiko Kagawa Okamoto Yasunobu Kimiko Sogabe Shiroh Fujii Hirokazu Miki Hideshima Teru Anderson C. Kenneth Masahiro Abe Selective inhibition of class-I HDAC induces myeloma cell death through targeting IRF4-Pim-2 axis The 9th JSH International Symposium 2018 in Kyoto 20180727 TKS-/presentations/18027793 Hirofumi Tenshin 天眞 寛文 Jumpei Teramachi 寺町 順平 Masahiro Hiasa 日浅 雅博 Kotaro Tanimoto 谷本 幸多朗 Mohannad Ashtar ASHTAR MOHANNAD Ariunzaya Bat-Erdene Masami Iwasa 岩佐 昌美 Takeshi Harada 原田 武志 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Itsuro Endo 遠藤 逸朗 Eiji Tanaka 田中 栄二 Toshio Matsumoto 松本 俊夫 Masahiro Abe 安倍 正博 TAK1阻害はTRAILによる破骨細胞活性化作用を遮断 させると同時にTRAILの抗骨髄腫作用を増強する Japanese Society for Bone and Mineral Research 日本骨代謝学会 第36回日本骨代謝学会学術集会 20180726 TKS-/presentations/18027792 Masahiro Hiasa 日浅 雅博 Jumpei Teramachi 寺町 順平 Hirofumi Tenshin 天眞 寛文 Kotaro Tanimoto 谷本 幸多朗 Mohannad Ashtar ASHTAR MOHANNAD Ariunzaya Bat-Erdene Masami Iwasa 岩佐 昌美 Takeshi Harada 原田 武志 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Itsuro Endo 遠藤 逸朗 Eiji Tanaka 田中 栄二 Toshio Matsumoto 松本 俊夫 Masahiro Abe 安倍 正博 カテプシンK阻害による多発性骨髄腫骨病変部の骨量 回復プロセスにおける骨細胞の役割． Japanese Society for Bone and Mineral Research 日本骨代謝学会 第36回日本骨代謝学会学術集会 20180726 TKS-/presentations/18027760 Jumpei Teramachi Hirofumi Tenshin Masahiro Hiasa Oda Asuka Takeshi Harada Shingen Nakamura Hirokazu Miki Tatsuji Haneji Itsuro Endo Toshio Matsumoto Masahiro Abe Therapeutic impact of TAK1 inhibition on myeloma tumor progression and bone destruction 8th International Workshop on Advances in the Molecular Pharmacology and Therapeutics of Bone and other Musculoskeletal Diseases and Cancer and Bone Society 2018 Meeting 20180630 TKS-/presentations/18027795 Kotaro Tanimoto 谷本 幸多朗 Masahiro Hiasa 日浅 雅博 Hirofumi Tenshin 天眞 寛文 Jumpei Teramachi 寺町 順平 小田 明日香 Mohannad Ashtar ASHTAR MOHANNAD Ariunzaya Bat-Erdene Masami Iwasa 岩佐 昌美 Kimiko Sogabe 曽我部 公子 大浦 雅弘 Takeshi Harada 原田 武志 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Itsuro Endo 遠藤 逸朗 Eiji Tanaka 田中 栄二 Toshio Matsumoto 松本 俊夫 Masahiro Abe 安倍 正博 神経切断による麻痺と免荷の骨髄腫の進展への影響． 日本骨免疫学会 第4回日本骨免疫学会 20180624 TKS-/presentations/18027794 Hirofumi Tenshin 天眞 寛文 Jumpei Teramachi 寺町 順平 Masahiro Hiasa 日浅 雅博 小田 明日香 Kotaro Tanimoto 谷本 幸多朗 Mohannad Ashtar ASHTAR MOHANNAD Ariunzaya Bat-Erdene Masami Iwasa 岩佐 昌美 Takeshi Harada 原田 武志 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Itsuro Endo 遠藤 逸朗 Eiji Tanaka 田中 栄二 Toshio Matsumoto 松本 俊夫 Masahiro Abe 安倍 正博 TAK1による破骨細胞に対するTRAILの生存・細胞死シグナル制御機構． 日本骨免疫学会 第4回日本骨免疫学会 20180624 TKS-/presentations/18027797 Takeshi Harada 原田 武志 Oda Asuka Jumpei Teramachi 寺町 順平 Bat-Erdene Ariunzaya Iwasa Masami 岩佐 昌美 Maeda Yusaku Shingen Nakamura 中村 信元 Oura Masahiro Shiroh Fujii 藤井 志朗 Hirokazu Miki 三木 浩和 Kumiko Kagawa 賀川 久美子 Hideshima Teru Anderson C. Kenneth Masahiro Abe 安倍 正博 HDAC1/3 inhibition disrupts the IRF4-Pim-2 pathway to induce effective myeloma cell death The 43rd Annual Meeting of the Japanese Society of Myeloma 20180512 TKS-/presentations/18027796 Masami Iwasa 岩佐 昌美 Takeshi Harada 原田 武志 Bat-Erdene Ariunzaya Ariunzaya Bat-Erdene 小田 明日香 前田 悠作 高橋 真美子 Masahiro Oura 大浦 雅博 Jumpei Teramachi 寺町 順平 Shiroh Fujii 藤井 志朗 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Kumiko Kagawa 賀川 久美子 Masahiro Abe 安倍 正博 Amplification of the IFN- γ -STAT1- PD-L1 pathway in myeloma cells by panobinostat パノビスタットによる骨髄腫細胞のIFN-γ-STAT1- PD-L1経路の増強 The 43rd Annual Meeting of the Japanese Society of Myeloma 20180512 TKS-/presentations/18027798 Shoko Iwahashi 岩橋 祥子 Mitsuo Shimada 島田 光生 Kouzou Yoshikawa 吉川 幸造 Jun Higashijima 東島 潤 Takuya Tokunaga 徳永 卓哉 Masaaki Nishi 西 正暁 Chie Takasu 須 千絵 Hideya Kashihara 柏原 秀也 Daichi Ishikawa 石川 大地 Hirokazu Miki 三木 浩和 Masahiro Oura 大浦 雅博 MDS・発作性夜間血色素尿症を合併する胃癌に対する手術が安全に施行可能であった1例 東京 第118回日本外科学会定期学術集会 20180405 TKS-/presentations/18027800 Hozumi Tashima 田島 穂澄 Youichi Sato 佐藤 陽一 Naoto Okada 岡田 直人 Shingen Nakamura 中村 信元 Kumiko Kagawa 賀川 久美子 Shiroh Fujii 藤井 志朗 Hirokazu Miki 三木 浩和 Keisuke Ishizawa 石澤 啓介 Masahiro Abe 安倍 正博 Aiko Yamauchi 山内 あい子 シタラビン投与による副作用発現と代謝経路関連遺伝子多型の関連解析 第56回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会 20171022 TKS-/presentations/18027799 Yuto Tanigaki 谷垣 雄都 Youichi Sato 佐藤 陽一 Yuta Yamaguchi 山口 裕大 Naoto Okada 岡田 直人 Shingen Nakamura 中村 信元 Kumiko Kagawa 賀川 久美子 Shiroh Fujii 藤井 志朗 Hirokazu Miki 三木 浩和 Keisuke Ishizawa 石澤 啓介 Masahiro Abe 安倍 正博 Aiko Yamauchi 山内 あい子 テイコプラニン投与による副作用発現および血中濃度とCYP遺伝子多型との関連解析 第56回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会 20171022 TKS-/presentations/18027801 Jumpei Teramachi Masahiro Hiasa Oda Asuka Hirofumi Tenshin Ryota Amachi Takeshi Harada Shingen Nakamura Masami Iwasa Masahiro Oura Yusaku Maeda Shiroh Fujii Kumiko Kagawa Hirokazu Miki Itsuro Endo Toshio Matsumoto Masahiro Abe Disruption of myeloma cell-bone marrow interaction by TAK-1 inhibition 第80回日本血液学会学術集会 20171020 TKS-/presentations/18027761 Jumpei Teramachi Masahiro Hiasa Oda Asuka Hirofumi Tenshin Ryota Amachi Takeshi Harada Shingen Nakamura Hirokazu Miki Itsuro Endo Tatsuji Haneji Toshio Matsumoto Masahiro Abe TAK1 inhibition impairs myeloma cell-bone marrow interaction to reduce myeloma tumor growth and bone destruction American Society for Bone and Mineral Research (ASBMR) 2017 Annual Meeting 20170908 TKS-/presentations/18027762 Jumpei Teramachi Masahiro Hiasa Oda Asuka Hirofumi Tenshin Ryota Amachi Takeshi Harada Shingen Nakamura Hirokazu Miki Itsuro Endo Tatsuji Haneji Toshio Matsumoto Masahiro Abe Therapeutic impact of TAK1 inhibition on myeloma tumor progression and bone destruction International Society for Experimental Hematology 46th Annual Scientific Meeting 20170824 TKS-/presentations/18027802 Hirofumi Tenshin 天眞 寛文 Jumpei Teramachi 寺町 順平 小田 明日香 Ryota Amachi 天知 良太 Masahiro Hiasa 日浅 雅博 Keiichiro Watanabe 渡邉 佳一郎 Ariunzaya Baterdene Masami Iwasa 岩佐 昌美 Shiroh Fujii 藤井 志朗 Kumiko Kagawa 賀川 久美子 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Itsuro Endo 遠藤 逸朗 Eiji Tanaka 田中 栄二 Toshio Matsumoto 松本 俊夫 Masahiro Abe 安倍 正博 TRAILは破骨細胞を活性化させるが，TAK1阻害により骨髄腫細胞とともに破骨細胞にもTRAILのアポトーシス誘導活性が惹起できる The 35th Annual Meeting of the Japanese Society for Bone and Mineral Research (oral talk) 第35回 日本骨代謝学会学術集会 20170729 TKS-/presentations/18027804 Yuta Yamaguchi 山口 裕大 Youichi Sato 佐藤 陽一 Yuto Tanigaki 谷垣 雄都 Naoto Okada 岡田 直人 Shingen Nakamura 中村 信元 Kumiko Kagawa 賀川 久美子 Shiroh Fujii 藤井 志朗 Hirokazu Miki 三木 浩和 Keisuke Ishizawa 石澤 啓介 Masahiro Abe 安倍 正博 Aiko Yamauchi 山内 あい子 バンコマイシン投与による副作用発現及び血中濃度とCYP遺伝子多型との関連解析 第20回日本医薬品情報学会総会・学術大会 20170709 TKS-/presentations/18027803 Rio Ohmori 大森 理央 Youichi Sato 佐藤 陽一 Misaki Kiguchi 木口 美沙妃 Naoto Okada 岡田 直人 Shingen Nakamura 中村 信元 Kumiko Kagawa 賀川 久美子 Shiroh Fujii 藤井 志朗 Hirokazu Miki 三木 浩和 Keisuke Ishizawa 石澤 啓介 Masahiro Abe 安倍 正博 Aiko Yamauchi 山内 あい子 ビンクリスチンによる副作用発現とMDR1遺伝子多型との関連性 第20回日本医薬品情報学会総会・学術大会 20170709 TKS-/presentations/18027805 李 悦子 瀧本 朋美 Naoki Oda 小田 直輝 Erika Niki 仁木 恵里加 伊藤 正一 荻山 佳子 Ken-ichi Suga 須賀 健一 Ryuji Nakagawa 中川 竜二 Hirokazu Miki 三木 浩和 Masahiro Abe 安倍 正博 抗Jra保有妊婦に重症胎児貧血を認め，児のJra抗原発現抑制が疑われた1症例 第65回日本輸血細胞治療学会総会 20170622 TKS-/presentations/18027763 Hirofumi Tenshin Jumpei Teramachi A Oda Ryota Amachi Masahiro Hiasa A Baterdene Keiichiro Watanabe Shingen Nakamura Hirokazu Miki Itsuro Endo Itsuro Endo Eiji Tanaka Toshio Matsumoto Masahiro Abe Osteoclasts utilize TRAIL for their NF-B activation, but TAK1 inhibition resumes TRAIL-induced apoptosis in osteoclasts. Australian and New Zealand Bone and Mineral Society 2017 20170617 TKS-/presentations/18027806 Hirofumi Tenshin 天眞 寛文 Jumpei Teramachi 寺町 順平 小田 明日香 Ryota Amachi 天知 良太 Masahiro Hiasa 日浅 雅博 Baterdene Ariunzaya Keiichiro Watanabe 渡邉 佳一郎 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Itsuro Endo 遠藤 逸朗 Eiji Tanaka 田中 栄二 Toshio Matsumoto 松本 俊夫 Masahiro Abe 安倍 正博 TAK1阻害はTRAILの抗骨髄腫作用を増強するともに骨吸収促進活性を抑制活性に変換する． 日本骨髄腫学会 第42回日本骨髄腫学会 20170528 TKS-/presentations/18027764 Jumpei Teramachi Masahiro Hiasa Oda Asuka Hirofumi Tenshin Ryota Amachi Takeshi Harada Shingen Nakamura Hirokazu Miki Itsuro Endo Akihito Yamamoto Tatsuji Haneji Toshio Matsumoto Masahiro Abe Therapeutic impact of TAK1 inhibition on myeloma tumor progression and bone destruction Cancer and Bone Society Conference 2017 20170504 TKS-/presentations/18027765 Ryota Amachi Masahiro Hiasa Oda Asuka Bat-Erdene Ariunzaya Jumpei Teramachi Hirofumi Tenshin Keiichiro Watanabe Shingen Nakamura Hirokazu Miki Kumiko Kagawa Shiroh Fujii Toshio Matsumoto Eiji Tanaka Masahiro Abe Osteoblast Creates a Non-permissive Niche for Myeloma Cells 95th General Session & Exhibition of the IADR program book 20170325 TKS-/presentations/18027807 Hirofumi Tenshin 天眞 寛文 Jumpei Teramachi 寺町 順平 小田 明日香 Ryota Amachi 天知 良太 Masahiro Hiasa 日浅 雅博 Keiichiro Watanabe 渡邉 佳一郎 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Itsuro Endo 遠藤 逸朗 Eiji Tanaka 田中 栄二 Toshio Matsumoto 松本 俊夫 Masahiro Abe 安倍 正博 30. 天真寛文, 寺町順平, 小田明日香, 天知良太, , ,破骨細胞系細胞はアポトーシス誘引因子TRAILを生存促進・破骨細胞形成誘導因子として利用する:TAK1-Pim-2経路の役割 第19回日本癌と骨病変研究会 20161111 TKS-/presentations/18027810 Ryota Amachi Masahiro Hiasa Jumpei Teramachi 小田 明日香 Hirofumi Tenshin Keiichiro Watanabe Shingen Nakamura Hirokazu Miki Kumiko Kagawa Shiroh Fujii 遠藤 逸郎 Eiji Tanaka Toshio Matsumoto Masahiro Abe Mechanism of the TRPV1 up-regulatation in myeloma cells and adaptation to an acidic microenvironment. 第77回日本血液学会学術集会, 20161016 TKS-/presentations/18027809 Hirofumi Tenshin Jumpei Teramachi 小田 明日香 Ryota Amachi Masahiro Hiasa Keiichiro Watanabe Shingen Nakamura Hirokazu Miki Itsuro Endo Eiji Tanaka Toshio Matsumoto Masahiro Abe TAK1 inhibition subverts TRAIL-mediated osteoclastogenesis. 第77回日本血液学会学術集会, 20161016 TKS-/presentations/18027808 Jumpei Teramachi Hiroshi Mori Yasuo Ochi Ryota Amachi Asuka Oda Masahiro Hiasa Takeshi Harada Shiroh Fujii Shingen Nakamura Hirokazu Miki Kumiko Kagawa Itsuro Endo Eiji Tanaka Toshio Matsumoto Masahiro Abe Potent induction of bone formation by anti-resorptive cathepsin K inhibitor in myeloma. The 77th Annual Meeting of the Japanese Society of Hematology 20161016 TKS-/presentations/18027811 Jumpei Teramachi Masahiro Hiasa Asuka Oda Hirofumi Tenshin Ryota Amachi Takeshi Harada Shingen Nakamura Kiyoe Kurahashi Takeshi Kondo Hirokazu Miki Itsuro Endo Tatsuji Haneji Toshio Matsumoto Masahiro Abe TAK-1 inhibition disrupts Pim-2-associated and Pim-2-independent key signaling pathways to effectively suppress tumor growth and restore bone formation in myeloma 第78回 日本血液学会学術集会 20161013 TKS-/presentations/18027766 Jumpei Teramachi Masahiro Hiasa Asuka Oda Hirofumi Tenshin Ryota Amachi Takeshi Harada Shingen Nakamura Kiyoe Kurahashi Takeshi Kondo Hirokazu Miki Itsuro Endo Toshio Matsumoto Masahiro Abe TAK-1 inhibition disrupts Pim-2-associated and Pim-2-independent key signaling pathways to effectively suppress tumor growth and restore bone formation in myeloma American Society for Bone and Mineral Research 2016 Annual Meeting 20160918 TKS-/presentations/18027813 Hirofumi Tenshin 天眞 寛文 Jumpei Teramachi 寺町 順平 小田 明日香 Ryota Amachi 天知 良太 Masahiro Hiasa 日浅 雅博 Keiichiro Watanabe 渡邉 佳一郎 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Itsuro Endo 遠藤 逸朗 Eiji Tanaka 田中 栄二 Toshio Matsumoto 松本 俊夫 Masahiro Abe 安倍 正博 破骨細胞はTAK1の発現誘導を介しアポトーシスを抑制しTRAILにより成熟活性化される 日本骨代謝学会学術集会プログラム抄録集 (1349-0761)34回 Page183(2016.07) 20160723 TKS-/presentations/18027812 Keiichiro Watanabe 渡邉 佳一郎 Jumpei Teramachi 寺町 順平 Ryota Amachi 天知 良太 小田 明日香 Hirofumi Tenshin 天眞 寛文 Masahiro Hiasa 日浅 雅博 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Itsuro Endo 遠藤 逸朗 川谷 誠 長田 裕之 Eiji Tanaka 田中 栄二 Toshio Matsumoto 松本 俊夫 Masahiro Abe 安倍 正博 リベロマイシンAによる酸性環境での骨髄腫細胞の治療抵抗性の克服 日本骨代謝学会学術集会プログラム抄録集 (1349-0761)34回 Page183(2016.07) 20160723 TKS-/presentations/18027814 Jumpei Teramachi 寺町 順平 Masahiro Hiasa 日浅 雅博 小田 明日香 Hirofumi Tenshin 天眞 寛文 Ryota Amachi 天知 良太 原田 武志 Keiichiro Watanabe 渡邉 佳一郎 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Itsuro Endo 遠藤 逸朗 Tatsuji Haneji 羽地 達次 Toshio Matsumoto 松本 俊夫 Masahiro Abe 安倍 正博 骨髄腫腫瘍進展と骨破壊病変形成におけるTAK1-Pim-2経路の役割 The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts 日本骨代謝学会学術集会プログラム抄録集 20160721 TKS-/presentations/18027767 Jumpei Teramachi Masahiro Hiasa Asuka Oda Hirofumi Tenshin Ryota Amachi Takeshi Harada Shingen Nakamura Hirokazu Miki Itsuro Endo Tatsuji Haneji Toshio Matsumoto Masahiro Abe Therapeutic impact of TAK-1 inhibition on tumor growth and bone destruction in myeloma 21st Congress European Hematology Association 20160609 TKS-/presentations/18027815 Jumpei Teramachi 寺町 順平 Masahiro Hiasa 日浅 雅博 小田 明日香 原田 武志 Hirofumi Tenshin 天眞 寛文 Shingen Nakamura 中村 信元 Ryota Amachi 天知 良太 Shiroh Fujii 藤井 志朗 Keiichiro Watanabe 渡邉 佳一郎 Kumiko Kagawa 賀川 久美子 Hirokazu Miki 三木 浩和 Itsuro Endo 遠藤 逸朗 Tatsuji Haneji 羽地 達次 Toshio Matsumoto 松本 俊夫 Masahiro Abe 安倍 正博 Pim-2は骨髄腫における破骨細胞形成促進の 必須媒介因子である 第41回日本骨髄腫学会学術集会 20160529 TKS-/presentations/18027816 Hirofumi Tenshin 天眞 寛文 Jumpei Teramachi 寺町 順平 小田 明日香 Ryota Amachi 天知 良太 Masahiro Hiasa 日浅 雅博 Keiichiro Watanabe 渡邉 佳一郎 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Itsuro Endo 遠藤 逸朗 Eiji Tanaka 田中 栄二 Toshio Matsumoto 松本 俊夫 Masahiro Abe 安倍 正博 TRAILは破骨細胞に細胞死を誘導せず，破骨細胞分化・生存を促進する. 第41回日本骨髄腫学会 20160528 TKS-/presentations/18027854 梶田 敬介 Shingen Nakamura 中村 信元 曽我部 公子 藤野 ひかる 丸橋 朋子 Shiroh Fujii 藤井 志朗 Hirokazu Miki 三木 浩和 Kumiko Kagawa 賀川 久美子 Hiroaki Toba 鳥羽 博明 阿部 正博 胸腺腫瘍に合併した赤芽球癆の二例-病態解明へのアプローチ- 第252回徳島医学会学術集会 20160214 TKS-/presentations/18027768 Jumpei Teramachi Masahiro Hiasa Asuka Oda Hirofumi Tenshin Ryota Amachi Takeshi Harada Derek Hanson Keiichiro Watanabe Shiroh Fujii Kumiko Kagawa Shingen Nakamura Hirokazu Miki Itsuro Endo Shuji Ozaki Toshio Matsumoto Masahiro Abe Pim inhibition suppresses osteoclastogenesis and tumor growth in myeloma 57th ASH Annual Meeting and Exposition 20151200 TKS-/presentations/18027817 Takayuki Ise 伊勢 孝之 西條 良仁 Hirokazu Miki 三木 浩和 Kumiko Kagawa 賀川 久美子 瀬野 弘光 上野 理絵 原 知也 齋藤 友子 Mika Bando 坂東 美佳 坂東 左知子 伊藤 浩敬 Tomomi Matsuura 松浦 朋美 Koji Yamaguchi 山口 浩司 Takeshi Tobiume 飛梅 威 Shusuke Yagi 八木 秀介 Hirotsugu Yamada 山田 博胤 Takeshi Soeki 添木 武 Tetsuzo Wakatsuki 若槻 哲三 Masahiro Abe 安倍 正博 Masataka Sata 佐田 政隆 auto-PBSCT とBortezomibの併用が著効した高度心機能障害を伴う原発性心アミロイドーシスの1例 第107回日本循環器学会四国地方会 20151114 TKS-/presentations/18027769 Ryota Amachi Masahiro Hiasa Jumpei Teramachi Asuka Oda Hirofumi Tenshin Keiichiro Watanabe Shingen Nakamura Hirokazu Miki Kumiko Kagawa Shiroh Fujii Itsuro Endo Eiji Tanaka Toshio Matsumoto Masahiro Abe Up-regulation of the pH sensor TRPV1 in myeloma cells and their adaption to an acidic microenvironment ASBMR 2015 Annual Meeting 20151010 TKS-/presentations/18027819 Jumpei Teramachi Masahiro Hiasa Asuka Oda Hirofumi Tenshin Ryota Amachi Takeshi Harada Keiichiro Watanabe Shiroh Fujii Kumiko Kagawa Shingen Nakamura Hirokazu Miki Itsuro Endo Tatsuji Haneji Toshio Matsumoto Masahiro Abe Tumor reduction and bone restoration in myeloma by TAK-1 inhibition 第77回日本血液学会学術集会 20151000 TKS-/presentations/18027818 Jumpei Teramachi 寺町 順平 Masahiro Hiasa 日浅 雅博 Asuka Oda Hirofumi Tenshin 天眞 寛文 Ryota Amachi 天知 良太 Takeshi Harada Keiichiro Watanabe 渡邉 佳一郎 Shiroh Fujii 藤井 志朗 Kumiko Kagawa 賀川 久美子 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Itsuro Endo 遠藤 逸朗 Tatsuji Haneji 羽地 達次 Toshio Matsumoto 松本 俊夫 Masahiro Abe 安倍 正博 Potent suppression of osteoclastogenesis in myeloma by Pim inhibition 第77回日本血液学会学術集会 20151000 TKS-/presentations/18027770 Jumpei Teramachi Masahiro Hiasa Asuka Oda Hirofumi Tenshin Ryota Amachi Takeshi Harada Keiichiro Watanabe Shiroh Fujii Kumiko Kagawa Shingen Nakamura Hirokazu Miki Itsuro Endo Tatsuji Haneji Toshio Matsumoto Masahiro Abe Pivotal role of TAK-1 in tumor growth and bone destruction in myeloma: Therapeutic impact of TAK-1 inhibition American Society for Bone and Mineral Research 2015 Annual Meeting 20151000 TKS-/presentations/18027772 Shingen Nakamura Hirokazu Miki Hirofumi Tenshin Ryota Amachi Keiichiro Watanabe Jumpei Teramachi Shiroh Fujii Kumiko Kagawa Masahiro Abe Alteration of Pim-2 expression by clinically available anti-myeloma agents: combinatory anti-myeloma effects with Pim inhibition Clinical Lymphoma, Myeloma & Leukemia 20150900 TKS-/presentations/18027771 Hirokazu Miki Shingen Nakamura Hirofumi Tenshin Ryota Amachi Keiichiro Watanabe Jumpei Teramachi Shiroh Fujii Kumiko Kagawa Masahiro Abe Effective impairment of myeloma progenitors by hyperthermia: augmentation with bortezomib and Pim inhibition in combination Clinical Lymphoma, Myeloma & Leukemia 20150900 TKS-/presentations/18027821 Jumpei Teramachi 寺町 順平 Masahiro Hiasa 日浅 雅博 小田 明日香 Hirofumi Tenshin 天眞 寛文 Ryota Amachi 天知 良太 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Itsuro Endo 遠藤 逸朗 Tatsuji Haneji 羽地 達次 Toshio Matsumoto 松本 俊夫 Masahiro Abe 安倍 正博 骨髄腫腫瘍進展と骨破壊病変形成における TAK-1の枢軸的役割 The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts 日本骨代謝学会学術集会プログラム抄録集 20150723 TKS-/presentations/18027820 Jumpei Teramachi 寺町 順平 Masahiro Hiasa 日浅 雅博 小田 明日香 Hirofumi Tenshin 天眞 寛文 Ryota Amachi 天知 良太 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Itsuro Endo 遠藤 逸朗 Tatsuji Haneji 羽地 達次 Toshio Matsumoto 松本 俊夫 Masahiro Abe 安倍 正博 Pim阻害による骨髄種骨病変の治療:破骨細胞形成の抑制 The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts 日本骨代謝学会学術集会プログラム抄録集 20150723 TKS-/presentations/18027825 Hirofumi Tenshin 天眞 寛文 Jumpei Teramachi 寺町 順平 小田 明日香 Ryota Amachi 天知 良太 Masahiro Hiasa 日浅 雅博 Keiichiro Watanabe 渡邉 佳一郎 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Itsuro Endo 遠藤 逸朗 Eiji Tanaka 田中 栄二 Toshio Matsumoto 松本 俊夫 Masahiro Abe 安倍 正博 アポトーシス誘導因子TRAILによる破骨細胞分化・生存の促進 The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts 日本骨代謝学会学術集会プログラム抄録集 20150700 TKS-/presentations/18027824 Ryota Amachi 天知 良太 Masahiro Hiasa 日浅 雅博 Jumpei Teramachi 寺町 順平 小田 明日香 Keiichiro Watanabe 渡邉 佳一郎 Hirofumi Tenshin 天眞 寛文 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Itsuro Endo 遠藤 逸朗 Takeshi Kondo 近藤 剛史 Eiji Tanaka 田中 栄二 Toshio Matsumoto 松本 俊夫 Masahiro Abe 安倍 正博 酸性環境での骨髄腫細胞のTRPV1の発現亢進と酸環境への適応 The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts 日本骨代謝学会学術集会プログラム抄録集 20150700 TKS-/presentations/18027823 Ryota Amachi 天知 良太 Masahiro Hiasa 日浅 雅博 Jumpei Teramachi 寺町 順平 小田 明日香 Hirofumi Tenshin 天眞 寛文 Keiichiro Watanabe 渡邉 佳一郎 Shingen Nakamura 中村 信元 Kumiko Kagawa 賀川 久美子 Hirokazu Miki 三木 浩和 Shiroh Fujii 藤井 志朗 Itsuro Endo 遠藤 逸朗 Eiji Tanaka 田中 栄二 Toshio Matsumoto 松本 俊夫 Masahiro Abe 安倍 正博 酸環境での骨髄腫細胞のDR4発現抑制:酸によるエピジェネティックな遺伝子発現制御 第1回日本骨免疫学会 20150701 TKS-/presentations/18027822 Hirofumi Tenshin 天眞 寛文 Jumpei Teramachi 寺町 順平 小田 明日香 Ryota Amachi 天知 良太 Keiichiro Watanabe 渡邉 佳一郎 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Itsuro Endo 遠藤 逸朗 Eiji Tanaka 田中 栄二 Toshio Matsumoto 松本 俊夫 Masahiro Abe 安倍 正博 TRAILは破骨細胞分化・生存を促進する:TAK-1による生と死の運命制御 第1回日本骨免疫学会 20150701 TKS-/presentations/18027826 Mikiko Takei 武井 美貴子 Mayo Kondo 近藤 真代 Seidai Satou 佐藤 正大 Hiroshi Kawano 河野 弘 Yuko Toyoda 豊田 優子 Masaki Hanibuchi 埴淵 昌毅 Yasuhiko Nishioka 西岡 安彦 Hirokazu Miki 三木 浩和 Kumiko Tanaka 田中 久美子 Tetsuji Takayama 高山 哲治 好酸球性胆管炎を合併した全身性エリテマトーデスの1例 第112回日本内科学会四国地方会 20150607 TKS-/presentations/18027828 Jumpei Teramachi 寺町 順平 Masahiro Hiasa 日浅 雅博 小田 明日香 原田 武志 Ryota Amachi 天知 良太 Hirofumi Tenshin 天眞 寛文 Hirokazu Miki 三木 浩和 Shingen Nakamura 中村 信元 Shiroh Fujii 藤井 志朗 Kumiko Kagawa 賀川 久美子 Itsuro Endo 遠藤 逸朗 Toshio Matsumoto 松本 俊夫 Masahiro Abe 安倍 正博 TAK-1は骨髄腫腫瘍進展と骨破壊病変形成の枢軸的な媒介因子である 第40回日本骨髄腫学会学術集会 20150516 TKS-/presentations/18027827 Jumpei Teramachi 寺町 順平 Masahiro Hiasa 日浅 雅博 小田 明日香 原田 武志 Ryota Amachi 天知 良太 Hirofumi Tenshin 天眞 寛文 Hirokazu Miki 三木 浩和 Shingen Nakamura 中村 信元 Shiroh Fujii 藤井 志朗 Kumiko Kagawa 賀川 久美子 Itsuro Endo 遠藤 逸朗 Toshio Matsumoto 松本 俊夫 Masahiro Abe 安倍 正博 Pim阻害による骨髄腫骨吸収亢進の抑制 第40回日本骨髄腫学会学術集会 20150516 TKS-/presentations/18027829 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Masahiro Abe 安倍 正博 Pim阻害薬と抗骨髄腫治療薬の併用効果の検討 第40回 日本骨髄腫学会 20150500 TKS-/presentations/18027830 Mayuri Nakano 中野 万有里 Terumi Yoshijima 吉嶋 輝実 Masaki Hanibuchi 埴淵 昌毅 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Kumiko Kagawa 賀川 久美子 Yasuhiko Nishioka 西岡 安彦 Pneumocystis jiroveciに対しST合剤の脱感作療法を行った4症例の検討 第89回日本感染症学会総会 20150416 TKS-/presentations/18027831 Shingen Nakamura 中村 信元 Momoyo Azuma 東 桃代 Hirokazu Miki 三木 浩和 Kumiko Kagawa 賀川 久美子 Masahiro Abe 安倍 正博 当院で経験した重症熱性血小板減少症候群の3例 第89回 日本感染症学会 20150400 TKS-/presentations/18027832 丸橋 朋子 Shingen Nakamura 中村 信元 曽我部 公子 八木 ひかる 高橋 真美子 宇高 憲吾 Shiroh Fujii 藤井 志朗 Hirokazu Miki 三木 浩和 Kumiko Kagawa 賀川 久美子 Masahiro Abe 安倍 正博 Atsuro Saijo 西條 敦郎 Mayuri Nakano 中野 万有里 Momoyo Azuma 東 桃代 Yasuhiko Nishioka 西岡 安彦 近藤 憲保 井内 新 藤田 博己 馬原 文彦 当院で経験した重症熱性血小板減少症候群の3例 第250回徳島医学会学術集会 20150201 TKS-/presentations/18027833 Jumpei Teramachi Masahiro Hiasa 原田 武志 Ryota Amachi Kumiko Kagawa Hirokazu Miki Shingen Nakamura Shiroh Fujii Itsuro Endo Toshio Matsumoto Masahiro Abe Therapeutic impact of Pim inhibition on myeloma bone disease: blockade of NF-B-mediated suppression of osteoblastogenesis and stimulation of osteoclastogenesis 日本血液学会 20141031 TKS-/presentations/18027773 Jumpei Teramachi Masahiro Hiasa 小田 明日香 Ryota Amachi Takeshi Harada Shingen Nakamura Kumiko Kagawa Hirokazu Miki Shiroh Fujii Keiichiro Watanabe Itsuro Endo Toshio Matsumoto Masahiro Abe Critical role of Pim-2 in NF-B-mediated suppression of osteoblastogenesis and stimulation of osteoclastogenesis: Therapeutic impact of Pim inhibition on myeloma bone disease. 2014 ASBMR Annual Meeting 20140913 TKS-/presentations/18027834 西條 良仁 Takayuki Ise 伊勢 孝之 Hirokazu Miki 三木 浩和 Kumiko Kagawa 賀川 久美子 原 知也 齋藤 友子 高島 啓 Mika Bando 坂東 美佳 坂東 左知子 Tomomi Matsuura 松浦 朋美 Junko Hotsuchi 發知 淳子 Koji Yamaguchi 山口 浩司 Takeshi Tobiume 飛梅 威 Shusuke Yagi 八木 秀介 Takashi Iwase 岩瀬 俊 Hirotsugu Yamada 山田 博胤 Takeshi Soeki 添木 武 Tetsuzo Wakatsuki 若槻 哲三 奥村 宇信 藤永 裕之 Masataka Sata 佐田 政隆 高度心機能障害を伴う原発性心アミロイドーシスに対しauto-PBSCTを施行し得た一例 第104回日本循環器学会中国・四国合同地方会 20140718 TKS-/presentations/18027855 Itsuro Endo 遠藤 逸朗 Kumiko Kagawa 賀川 久美子 Hirokazu Miki 三木 浩和 高橋 真美子 Masahiro Abe 安倍 正博 B細胞リンパ腫を合併した先端巨大症の一例 第3回四国GH/IGF1フォーラム 20140208 TKS-/presentations/18027856 Ryota Amachi 天知 良太 Masahiro Abe 安倍 正博 Keiichiro Watanabe 渡邉 佳一郎 Kumiko Kagawa 賀川 久美子 Shiroh Fujii 藤井 志朗 原田 武志 Hirokazu Miki 三木 浩和 Keiichiro Watanabe 渡邉 佳一郎 小野 明日香 Masahiro Hiasa 日浅 雅博 Eiji Tanaka 田中 栄二 Toshio Matsumoto 松本 俊夫 骨髄腫の酸性環境はTRAIL受容体発現をエピジェネティックに抑制し，TRAIL抵抗性をもたらす 第20回徳島骨代謝研究会 20131121 TKS-/presentations/18027835 近藤 直樹 藤田 拓朗 河上 和代 野上 浩子 守時 政宏 西岡 聡 西島 陽子 祖父江 理 森脇 久美子 原 大雅 河野 雅和 久保 治信 田中 勉 渡瀬 謙仁 Akira Mima 美馬 晶 高橋 利和 Toshio Doi 土井 俊夫 Hirokazu Miki 三木 浩和 Masahiro Abe 安倍 正博 免疫抑制療法実施中に赤芽球癆再発した血液透析患者の1例 第58回日本透析医学会総会 20130620 TKS-/presentations/18027836 Michihiro Nakamura 中村 教泰 Koichiro Hayashi 林 幸壱朗 Hirokazu Miki 三木 浩和 Shuji Ozaki 尾崎 修治 Masahiro Abe 安倍 正博 Toshio Matsumoto 松本 俊夫 Kazunori Ishimura 石村 和敬 有機シリカ・マルチ蛍光ナノプローブによるSeamless蛍光イメーシング 第8回日本分子イメージング学会学術集会 20130531 TKS-/presentations/18027775 Ryota Amachi Keiichiro Watanabe Shiroh Fujii T Harada Hirokazu Miki Shingen Nakamura A Oda Masahiro Hiasa Eiji Tanaka Toshio Matsumoto Masahiro Abe An acidic milieu suppersses histone acetylation in myeloma cells to down-regulate the TRAIL receptor DR4 expression. 20130400 TKS-/presentations/18027774 Keiichiro Watanabe Masahiro Abe Ryota Amachi Masahiro Hiasa T Harada Shiroh Fujii Shingen Nakamura Hirokazu Miki Kumiko Kagawa H Mori Itsuro Endo Eiji Tanaka Toshio Matsumoto Induction of bone formation in myeloma osteolytic lesions by cathepsinK inhibition 20130400 TKS-/presentations/18027837 長尾 多美子 畑 美智子 Hirokazu Miki 三木 浩和 Shoji Sakiyama 先山 正二 Hajime Koyama 小山 一 中心静脈カテーテル内腔のバイオフィルム形成に関わる因子の検索 第28回日本環境感染学会総会 20130301 TKS-/presentations/18027777 T Harada Shuji Ozaki A Oda M Iwasa Shiroh Fujii Shingen Nakamura Hirokazu Miki Kumiko Kagawa Masahiro Abe Hirofumi Shibata Akishige Ikegame Daisuke Tsuji Kouji Itou M Ri S Iida Y Shiotsu S Kawai H Yamada-Okabe Toshio Matsumoto Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Induces Marked Antibody-Dependent Cellular Cytotoxicity and Inhibits the Clonogenic Potential of Myeloma Cancer Stem-Like Cells. 54th ASH Annual Meeting and Exposition 20121208 TKS-/presentations/18027776 Harada Takeshi Ozaki Shuji Oda Asuka Iwasa Masami Shiroh Fujii Shingen Nakamura Hirokazu Miki Kumiko Kagawa Masahiro Abe Shibata Hironobu Akishige Ikegame Daisuke Tsuji Ito Kohji Ri Masaki Iida Shinsuke Shiotsu Yukimasa Kawai Shigeto Yamada-Okabe Hisafumi Toshio Matsumoto Combination therapy of a defucosylated anti-HM1.24 monoclonal antibody plus Ienalidomide induces marked antibody-dependent cellular cytotoxicity and inhibits the clonogenic potential of myeloma cancer stem-like cells. Atlanta, Dec. 2012. The 54th Annual Meeting of the American Society of Hamatology 20121208 TKS-/presentations/18027838 Hirokazu Miki 三木 浩和 Shingen Nakamura 中村 信元 竹内 恭子 原田 武志 岩佐 昌美 Shiroh Fujii 藤井 志朗 Kumiko Kagawa 賀川 久美子 Masahiro Abe 安倍 正博 Toshio Matsumoto 松本 俊夫 赤芽球癆を合併した多中心性Castleman病の1例 日本内科学会第107回四国地方会 20121202 TKS-/presentations/18027839 小田 直輝 李 悦子 松本 真弓 高松 典道 Hirokazu Miki 三木 浩和 Toshio Matsumoto 松本 俊夫 輸血後7日目にIgG抗E抗体を酵素法にて強く検出した一症例 第45回中四国支部医学検査学会 20121103 TKS-/presentations/18027841 Masahiro Hiasa Masahiro Abe Kumiko Kagawa Hirokazu Miki Shingen Nakamura Harada Takeshi Fujii Shirou Keiichiro Watanabe Ryota Amachi Kenzo Asaoka Toshio Matsumoto Pim-2 acts as a common downstream mediator to suppress bone formation in myeloma. 日本血液学会 第74回に本血液学会 20121020 TKS-/presentations/18027840 Shiroh Fujii 藤井 志朗 Masahiro Abe 安倍 正博 Ryota Amachi 天知 良太 Keiichiro Watanabe 渡邉 佳一郎 Masahiro Hiasa 日浅 雅博 竹内 恭子 岩佐 昌美 原田 武志 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Kumiko Kagawa 賀川 久美子 Toshio Matsumoto 松本 俊夫 Pim inhibition preferentially induces anti-myeloma activity in an acidic milien 第74回日本血液学会学術集会 20121020 TKS-/presentations/18027778 Masahiro Hiasa Ryota Amachi Keiichiro Watanabe Harada Takeshi Fujii Shirou Shingen Nakamura Hirokazu Miki Kumiko Kagawa Itsuro Endo Toshio Matsumoto Masahiro Abe Pim-2 suppresses BMP-2 signaling as a common inhibitory mediator of osteoblastogenesis in myeloma The American Society for Bone and Mineral Research ASBMR 2012 Anuual Meeting 20121015 TKS-/presentations/18027842 李 悦子 瀧本 朋美 松本 真弓 Kazuhisa Maeda 前田 和寿 Shuji Ozaki 尾崎 修治 Hirokazu Miki 三木 浩和 Toshio Matsumoto 松本 俊夫 血液型検査から無症候性の低ガンマグロブリン血症が判明し，周産期の感染予防に貢献し得た一例 第57回日本輸血・細胞治療学会中国四国地方会 20120929 TKS-/presentations/18027843 原田 武志 Shuji Ozaki 尾崎 修治 岩佐 昌美 Shiroh Fujii 藤井 志朗 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Kumiko Kagawa 賀川 久美子 柴田 泰伸 重清 俊雄 岡田 直人 長尾 多美子 鈴木 麗子 Shoji Sakiyama 先山 正二 Masahiro Abe 安倍 正博 Toshio Matsumoto 松本 俊夫 徳島県のエイズ拠点病院におけるHIV感染症及び後天性免疫不全症候群の現状 第245回徳島県医学会学術総会 20120729 TKS-/presentations/18027857 Ryota Amachi 天知 良太 Masahiro Abe 安倍 正博 Keiichiro Watanabe 渡邉 佳一郎 Kumiko Kagawa 賀川 久美子 藤井 志郎 原田 武志 Hirokazu Miki 三木 浩和 Shingen Nakamura 中村 信元 小田 明日香 Masahiro Hiasa 日浅 雅博 Eiji Tanaka 田中 栄二 Toshio Matsumoto 松本 俊夫 酸環境は骨髄腫細胞のTRAILに対する抵抗性を増強する 第3回骨バイオサイエンス研究会 20120714 TKS-/presentations/18027844 大黒 由加里 Shingen Nakamura 中村 信元 岩佐 昌美 原田 武志 Shiroh Fujii 藤井 志朗 Kumiko Kagawa 賀川 久美子 Masahiro Abe 安倍 正博 Toshio Matsumoto 松本 俊夫 Hirokazu Miki 三木 浩和 腰痛と副腎不全症状で発症した両側副腎原発DLBCLの1例 日本内科学会第106回四国地方会 20120611 TKS-/presentations/18027845 Michihiro Nakamura 中村 教泰 Koichiro Hayashi 林 幸壱朗 Aziz Awaad Hirokazu Miki 三木 浩和 Shuji Ozaki 尾崎 修治 Masahiro Abe 安倍 正博 Toshio Matsumoto 松本 俊夫 Kazunori Ishimura 石村 和敬 有機シリカ粒子技術を用いた近赤外蛍光ナノプローブの作製とユニバーサル蛍光イメージング 第7回日本分子イメージング学会学術集会 20120525 TKS-/presentations/18027846 原田 武志 Shiroh Fujii 藤井 志朗 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 中野 綾子 Kumiko Kagawa 賀川 久美子 竹内 恭子 Masahiro Abe 安倍 正博 Toshio Matsumoto 松本 俊夫 徳島県における多発性骨髄腫の治療成績の検討 第109回日本内科学会総会・講演会 20120413 TKS-/presentations/18027847 原田 武志 Shuji Ozaki 尾崎 修治 小田 明日香 天羽 宏枝 Shiroh Fujii 藤井 志朗 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 中野 綾子 Kumiko Kagawa 賀川 久美子 竹内 恭子 Masahiro Abe 安倍 正博 柴田 泰伸 Toshio Matsumoto 松本 俊夫 Lenalidomide 治療中の多発性骨髄腫患者におけるCRP上昇の検討 第51回日本血液学会中国四国地方会 20120303 TKS-/presentations/18027848 Kumiko Kagawa 賀川 久美子 原田 武志 Shiroh Fujii 藤井 志朗 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 竹内 恭子 Masahiro Abe 安倍 正博 Toshio Matsumoto 松本 俊夫 遺伝子組み替えヒトトロンボモジュリン投与中に硬膜下血腫を来した同腫骨髄移植2症例 第34回日本造血細胞移植学会 20120225 TKS-/presentations/18027849 Kumiko Kagawa 賀川 久美子 原田 武志 Shiroh Fujii 藤井 志朗 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 竹内 恭子 Masahiro Abe 安倍 正博 Toshio Matsumoto 松本 俊夫 遺伝子組み換えヒトトロンボモジュリン投与中に硬膜下血腫を来した同腫骨髄移植2症例 第34回日本造血細胞移植学会 20120200 TKS-/presentations/18027858 Masahiro Hiasa 日浅 雅博 Masahiro Abe 安倍 正博 中野 綾子 Keiichiro Watanabe 渡邉 佳一郎 Kyoko Takeuchi 竹内 恭子 Kumiko Kagawa 賀川 久美子 Hirokazu Miki 三木 浩和 Shingen Nakamura 中村 信元 Shiroh Fujii 藤井 志朗 原田 武志 Shuji Ozaki 尾崎 修治 Eiji Tanaka 田中 栄二 Kenzo Asaoka 淺岡 憲三 Toshio Matsumoto 松本 俊夫 Pimキナーゼの阻害による骨髄腫の進展抑制 癌と骨病変研究会 20111118 TKS-/presentations/18027850 Keiichiro Watanabe Masahiro Abe Q Cui Masahiro Hiasa M Kawatani T Harada Shiroh Fujii Shingen Nakamura Hirokazu Miki A Nakano K Kagawa K Takeuchi H Osada Eiji Tanaka Toshio Matsumoto Targeting an acidic microenvironment by reveromycin A to overcome drug resistance to myeloma cells and ameliorate bone disease. 第36回日本骨髄腫研究会総会 20111112 TKS-/presentations/18027851 Masahiro Hiasa 日浅 雅博 Masahiro Abe 安倍 正博 中野 綾子 Kyoko Takeuchi 竹内 恭子 Kumiko Kagawa 賀川 久美子 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Eiji Tanaka 田中 栄二 Kenzo Asaoka 淺岡 憲三 Ken-ichiro Yata 矢田 健一郎 Toshio Matsumoto 松本 俊夫 Pimキナーゼ阻害による腫瘍進展と骨破壊の抑制 第73回日本血液学会 20111014 TKS-/presentations/18027780 Masahiro Hiasa nakano ayako Keiichiro Watanabe C Qu T Harada Shiroh Fujii Hirokazu Miki Shingen Nakamura Kumiko Kagawa Kyoko Takeuchi Eiji Tanaka Kenzo Asaoka Shuji Ozaki Toshio Matsumoto Masahiro Abe Prevention of tumor growth and bone destruction in myeloma by Pim kinase inhibition. ASBMR 2011 Annual Meeting 20110917 TKS-/presentations/18027779 Keiichiro Watanabe Masahiro Abe M Kawatani Masahiro Hiasa A Kawano T Jinno T Harada Shiroh Fujii Shingen Nakamura Hirokazu Miki Kumiko Kagawa Kyoko Takeuchi Shuji Ozaki Eiji Tanaka H Osada Toshio Matsumoto Aggravation of myeloma growth and drug resistance by an acidic created in myeloma-osteoclast interaction. ASBMR 2011 Annual Meeting 20110917 TKS-/presentations/18027781 Masahiro Hiasa nakano ayako Keiichiro Watanabe C Qu T Harada Shiroh Fujii Hirokazu Miki Shingen Nakamura Kumiko Kagawa Kyoko Takeuchi Eiji Tanaka Kenzo Asaoka Shuji Ozaki Toshio Matsumoto Masahiro Abe Dual effects of Pim inhibition on myeloma: induction of bone formation and tumor suppression. IOF-ANZBMS 2011 Annual Meeting 20110906 TKS-/presentations/18027852 Kumiko Kagawa 賀川 久美子 Ken-ichiro Yata 矢田 健一郎 田中 修 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Kyoko Takeuchi 竹内 恭子 Masahiro Abe 安倍 正博 Shuji Ozaki 尾崎 修治 Sumiko Yoshida 吉田 守美子 Itsuro Endo 遠藤 逸朗 心筋への広範な直接浸潤を来したNK/T cell lymphoma 鼻型の一例 第48回に本血液学会中国四国地方会 20090307 TKS-/books_etc/14403650 Hirokazu Miki 三木 浩和 Masahiro Abe 安倍 正博 アミロイド原性light chainの脾臓での産生 ALアミロイドーシス，多発性骨髄腫の類縁疾患 Iyaku Journal Co., Ltd. 医薬ジャーナル社 20140812 TKS-/books_etc/14403651 Hirokazu Miki 三木 浩和 Masahiro Abe 安倍 正博 多発性骨髄腫に対する合併症の治療(腎，骨，感染症) 20121020 Hirofumi Tenshin 天眞 寛文 Jumpei Teramachi 寺町 順平 A Oda Ryota Amachi 天知 良太 Masahiro Hiasa 日浅 雅博 A Baterdene Keiichiro Watanabe 渡邉 佳一郎 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Itsuro Endo 遠藤 逸朗 Eiji Tanaka 田中 栄二 Toshio Matsumoto 松本 俊夫 Masahiro Abe 安倍 正博 Australian and New Zealand Bone and Mineral Society ANZBMS Plenary Poster Award. Osteoclasts utilize TRAIL for their NF-B activation, but TAK1 inhibition resumes TRAIL-induced apoptosis in osteoclasts. 20170617 Hirofumi Tenshin 天眞 寛文 Jumpei Teramachi 寺町 順平 小田 明日香 Ryota Amachi 天知 良太 Masahiro Hiasa 日浅 雅博 Keiichiro Watanabe 渡邉 佳一郎 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Itsuro Endo 遠藤 逸朗 Eiji Tanaka 田中 栄二 Toshio Matsumoto 松本 俊夫 Masahiro Abe 安倍 正博 Japanese Society for Bone and Mineral Research 日本骨代謝学会 第34回日本骨代謝学会学術集会・第3回アジア太平洋骨代謝学会議,Young investigator award. 破骨細胞はTAK1の発現誘導を介しアポトーシスを抑制しTRAILにより成熟活性化される 20160721 Keiichiro Watanabe 渡邉 佳一郎 Masahiro Abe 安倍 正博 H Mori R Amachi Masahiro Hiasa 日浅 雅博 T Harada Shiroh Fujii 藤井 志朗 Shingen Nakamura 中村 信元 Hirokazu Miki 三木 浩和 Kumiko Kagawa 賀川 久美子 Itsuro Endo 遠藤 逸朗 Eiji Tanaka 田中 栄二 Toshio Matsumoto 松本 俊夫 The American Society for Bone and Mineral Research 米国骨代謝学会 Plenary poster & Young Investigator Travel Award 5. Potent induction of bone formation in myeloma bone lesions by the cathepsin K inhibitor KK1-300-01 in combinat ion with the proteasome inhibitor bortezomib. 20131000